



Published in final edited form as:

*Nat Rev Mol Cell Biol.* 2016 August ; 17(8): 480–495. doi:10.1038/nrm.2016.62.

## Transcriptional and epigenetic control of brown and beige adipose cell fate and function

Takeshi Inagaki<sup>1,2</sup>, Juro Sakai<sup>1,2</sup>, and Shingo Kajimura<sup>3</sup>

<sup>1</sup>Division of Metabolic Medicine, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan 153–8904

<sup>2</sup>The Translational Systems Biology and Medicine Initiative (TSBMI), Center for Disease Biology and Integrative Medicine, Faculty of Medicine, The University of Tokyo, Tokyo, Japan 113–8655

<sup>3</sup>UCSF Diabetes Center and Department of Cell and Tissue Biology, University of California, San Francisco, California 94143–0669, USA

### Abstract

White adipocytes store excess energy in the form of triglycerides, whereas brown and beige adipocytes dissipate energy in the form of heat. This thermogenic function relies on the activation of brown and beige adipocyte-specific gene programmes that are coordinately regulated by adipose-selective chromatin architectures and by a set of unique transcriptional and epigenetic regulators. A number of transcriptional and epigenetic regulators are also required for promoting beige adipocyte biogenesis in response to various environmental stimuli. A better understanding of the molecular mechanisms governing the generation and function of brown and beige adipocytes is necessary to allow us to control adipose cell fate and stimulate thermogenesis. This may provide a therapeutic approach for the treatment of obesity and obesity-associated diseases, such as type 2 diabetes.

---

Adipose tissue has a central role in whole-body energy homeostasis. White adipose tissue (WAT) is the major adipose organ in mammals. It represents 10% or more of the body weight of healthy adult humans and is specialized for the storage of excess energy. Humans and rodents, however, possess an additional form of adipose tissue, known as brown adipose tissue (BAT), which is specialized to dissipate chemical energy in the form of heat. Evolutionarily, BAT functions as a defence mechanism against hypothermia, particularly in infants, small mammals and hibernating animals.

The best-known function of BAT is its thermogenic capacity, enabled by the BAT-selective expression of uncoupling protein 1 (UCP1), which stimulates thermogenesis by uncoupling cellular respiration and mitochondrial ATP synthesis. This thermogenic capacity of BAT has gained significant attention owing to its potential application in the amelioration of obesity and obesity-related diseases, such as insulin resistance, type 2 diabetes and fatty liver

---

Correspondence to S.K. skajimura@diabetes.ucsf.edu.

#### Competing interests statement

The authors declare no competing interests.

diseases (reviewed in REF. 1). Several human studies with  $^{18}\text{F}$ -fluoro-labelled 2-deoxy-glucose positron emission tomography ( $^{18}\text{F}$ FDG-PET) scanning indicate that the increased mass of  $^{18}\text{F}$ FDG-PET-positive BAT (which may result from, for example, increased BAT mass or thermogenic activity of existing BAT) is inversely correlated with body mass index (BMI), adiposity or fasting plasma glucose level in adult humans<sup>2-5</sup>. Recent studies in adult humans further demonstrated that chronic cold exposure stimulates the recruitment of new  $^{18}\text{F}$ FDG-PET-positive BAT even in subjects who had previously lacked detectable BAT depots before cold exposure, presumably owing to the emergence of new thermogenic adipocytes. This, then, leads to an increase in non-shivering thermogenesis and/or an improvement in insulin sensitivity<sup>6-9</sup>. These findings collectively support the significance of BAT in the regulation of energy expenditure and glucose homeostasis in adult humans.

Recent studies indicate that at least two distinct types of thermogenic adipocyte exist in mammals: a pre-existing form established during development, termed classical brown adipocytes; and an inducible form, termed beige (or brite) adipocytes. Classical brown adipocytes develop prenatally from a subset of dermomyotome cells and are localized predominantly in dedicated BAT depots, such as in the inter-scapular regions of rodents and human infants. The infant interscapular BAT depots eventually disappear in adult humans<sup>10,11</sup>. By contrast, beige adipocytes emerge postnatally from WAT, but the exact origin of these cells is much less well understood. A notable feature of beige fat is that beige adipocyte biogenesis is highly inducible by various environmental cues, such as chronic cold exposure, exercise and treatment with the agonist of the major regulator of adipogenesis, peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ; discussed in more detail below), in a process referred to as the 'browning' or 'beige-ing' of white fat (reviewed in REF. 12). Notably, UCP1-positive adipocytes from adult human BAT in the supraclavicular region possess molecular signatures that resemble murine beige adipocytes rather than classical brown adipocytes<sup>11,13-15</sup>. It has also been shown that human beige adipocytes can be derived from capillaries of subcutaneous WAT<sup>16</sup>, further illuminating the inducible nature of beige adipocytes and indicating their relevance to adult humans. This is important, because promoting the browning of white fat may be applicable for the treatment of obesity and type 2 diabetes, especially in subjects who do not possess appreciable levels of existing BAT, including obese, diabetic and elderly individuals.

One of the major advances in the field of BAT biology was the identification of essential transcriptional regulators and cascades, which are involved in brown and beige adipocyte development and their thermogenic function. For instance, ectopic expression of a dominant determination factor of brown adipose cell fate, PRDM16 (PR domain zinc-finger protein 16), and its binding partners CCAAT/enhancer-binding protein- $\beta$  (C/EBP $\beta$ ) and PPAR $\gamma$ , is sufficient to convert non-adipogenic cells in humans and mice, including skin fibroblasts and myoblasts, into brown adipose lineage<sup>17-19</sup>. These studies open up a new opportunity to manipulate the amount or the thermogenic function of brown and beige adipocytes *in vivo*. A better understanding of such mechanisms will further enable us to gain control over this thermogenic organ with ease and safety, which may provide a novel therapeutic intervention against obesity and obesity-related diseases. In this Review, we describe recent advances in the elucidation of transcriptional and epigenetic regulation of brown and beige adipocyte development, and delineate emerging questions in the field.

## Chromatin landscapes in adipocytes

Adipocyte differentiation occurs through commitment from multipotent stem cells to pre-adipocytes, and terminal differentiation from pre-adipocytes to mature adipocytes. These processes are regulated by the expression of lineage-specific transcriptional regulators and by changes in histone marks and chromatin conformation at specific developmental stages, which collectively generate unique chromatin landscapes associated with adipogenesis. Here, we describe the major features of chromatin in brown and beige adipocyte lineages.

### Major transcriptional regulators of adipogenesis

In contrast to our relatively limited knowledge regarding the commitment phase, a large number of adipogenic transcription factors have been identified that control adipocyte differentiation (reviewed in REF. 20). PPAR $\gamma$  and C/EBP $\alpha$ ,  $\beta$  and  $\delta$  are the principal adipogenic regulators involved in the differentiation of adipocytes. In the mouse 3T3-L1 pre-adipocyte cell line (one of the best-characterized models of adipogenesis), expression of C/EBP $\beta$  and C/EBP $\delta$  is quickly induced within 4 hours post-differentiation and subsequently activates the transcription of PPAR $\gamma$  and CEBP $\alpha$ . Subsequently, PPAR $\gamma$  and C/EBP $\alpha$  activate each other's expression and coordinately induce a number of genes that define terminally differentiated adipocyte phenotypes. PPAR $\gamma$  and C/EBP $\alpha$  are also important regulators of the thermogenic programme of brown and beige adipocytes (reviewed in REF. 21). As PPAR $\gamma$ -deficient mouse models (tetraploid-rescued or chimeric PPAR $\gamma$ -null mice) possess no brown or white adipose tissues, PPAR $\gamma$  is required for the development of both white and brown adipocytes<sup>22,23</sup>. However, PPAR $\gamma$  overexpression in fibroblasts or mesenchymal cells drives them into white but not brown adipocyte cell lineage, leading to the hypothesis that additional transcriptional components that cooperate with PPAR $\gamma$  and C/EBPs are necessary to induce the brown fat-selective gene programme<sup>21,24</sup>.

As described in more detail below, recent studies identified approximately 50 transcriptional and epigenetic regulators that positively or negatively regulate brown and beige adipocyte development (summarized in TABLE 1). It is notable that many, if not all, such regulators function through four transcriptional regulators: PPAR $\gamma$ , C/EBP $\beta$ , PPAR $\gamma$  co-activator-1 $\alpha$  (PGC1 $\alpha$ ) and PRDM16. PPAR $\gamma$  and C/EBP $\beta$  function as transcription factors and bind to DNA directly. PRDM16, which is a 140 kDa zinc-finger nuclear protein that promotes brown adipocyte differentiation and represses myogenesis<sup>17,19</sup>, was also initially considered to function primarily through direct binding to a specific DNA sequence via the zinc-finger domains<sup>25</sup>. However, a point mutation in PRDM16 that disrupts its DNA binding did not affect its ability to promote brown adipogenesis, indicating that PRDM16 is a transcriptional co-regulator<sup>18</sup>. Indeed, PRDM16 forms a transcriptional complex with canonical DNA-binding transcription factors such as PPAR $\gamma$  and C/EBP $\beta$ , through its zinc-finger domains, to specify and activate the BAT-selective gene programme<sup>17,19</sup>. More recently, analysis of PRDM16 by chromatin immunoprecipitation coupled to sequencing (ChIP-seq) showed that a large proportion of PRDM16 target genes are co-localized with binding sites of PPAR $\gamma$  and C/EBPs<sup>26</sup>, further supporting its co-regulatory functions.

## Chromatin features

In order to activate adipocyte-specific genes, master transcriptional regulators (such as PPAR $\gamma$ ) are recruited to adipocyte-specific gene loci. This is coupled to the establishment of cell type-specific histone and DNA modifications, which coordinate the binding of transcriptional regulators<sup>27,28</sup> (BOX 1). In fact, only 4% of PPAR $\gamma$ -binding sites in 3T3-L1 adipocytes are found in mouse macrophages that also express PPAR $\gamma$ <sup>29</sup>, underlining the importance of the establishment of distinct chromatin landscapes for correct fate specification during adipogenesis.


### Box 1

#### The role of chromatin modifications in cell fate specification

Pluripotent stem cells can differentiate into various types of somatic cell. Although stem cells share genome sequences with terminally differentiated cells, they gradually acquire cell type-specific characteristics by expressing lineage-specific genes (for example peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) for adipocytes) at an appropriate time point of differentiation. Stage-specific gene expression patterns, and thus cell fate determination, are tightly coupled to epigenetic chromatin changes such as DNA methylation, histone modifications (including acetylation and methylation), and chromatin remodelling regulated by chromatin remodelling proteins and transcription factors. Chromatin remodelling, such as mobilization, ejection and restructuring of nucleosomes, alters the recruitment of the transcriptional complex, thus regulating gene transcription.

In embryonic stem cells (ES cells), high expression of pluripotent genes is maintained owing to the ES cell-specific chromatin state on the pluripotent gene loci. The ‘active’ chromatin state is characterized by acetylated histone H3 Lys27 (H3K27ac) marks at enhancer regions, trimethylated H3K3 (H3K4me3) marks at promoter regions and DNA hypomethylation at promoter regions<sup>118–120</sup> (see the figure, top left panel; reviewed in REF. 121). By contrast, lineage-specific genes are stably silenced or expressed at very low levels in ES cells. The lineage-specific gene loci are associated with repressive H3K27me3 and active H3K4me3 marks (see the figure, top right panel). These bivalent histone marks keep the lineage-specific gene in a ‘poised’ state by pausing the promoter-proximal RNA polymerase II (Pol II)<sup>122,123</sup>.

In differentiated cells, heterochromatin (transcriptionally inactive chromatin), as characterized by H3K9me3 and H3K27me3 marks and DNA methylation, is found at the promoter regions of pluripotent genes, leading to stable repression of pluripotent gene expression<sup>119,124</sup> (see the figure, bottom left panel). By contrast, bivalent histone marks at lineage-specific genes are resolved to a monovalent mark of either H3K4me3 or H3K27me3 upon induction of differentiation<sup>124</sup>. The activated lineage-specific genes are associated with H3K4me3 at promoter regions and H3K4me1 and H3K27ac at enhancer regions. On the other hand, silenced genes (that is, genes not expressed in the lineage in question) are associated with H3K27me3 and DNA methylation at promoter regions (see the figure, bottom middle and bottom right panels).



A genome-wide analysis of chromatin states in embryonic stem cells (ES cells), mesenchymal stem cells and 3T3-L1 pre-adipocytes revealed that the bivalent trimethyl marks on histone H3 Lys residues (H3K4me3 and H3K27me3) at the *Pparg* and *Cebpa* gene loci are specific to ES cells and are not observed in mesenchymal stem cells or pre-adipocytes<sup>30</sup>. In preadipocytes, on the other hand, the bivalent H3K4me3 and H3K9me3 marks are found at the *Pparg* and *Cebpa* gene loci and seem to establish a ‘poised’ chromatin state that is prepared for active transcription upon induction (FIG. 1a). During the early phase of adipocyte differentiation (assessed with the use of the 3T3-L1 cell line), the bivalent H3K4me3 and H3K9me3 marks are resolved to a monovalent H3K4me3 mark, which activates transcription. Accordingly, phosphorylated C/EBP $\beta$  and its associated complexes with other transcription regulators, such as STAT5A (signal transducer and activator of transcription 5A), glucocorticoid receptor and Mediator complexes, are recruited to transcription factor binding sites during the early phase (~4 hours) of adipocyte differentiation and activate the expression of PPAR $\gamma$ <sup>31</sup>.

DNase I hypersensitive site analysis coupled with next generation sequencing (DHS-seq; see BOX 2 for technical terms) also showed that chromatin opening peaks at 4 hours after initiation of adipocyte differentiation and gradually decreases towards the end of differentiation (6 days post induction of differentiation)<sup>31</sup>. These spatiotemporal dynamics in chromatin architecture may be attributed to the function of pioneer factors, which can bind to loci marked with activated histone marks and initiate chromatin opening. Subsequently, PPAR $\gamma$  forms a heterodimeric complex with retinoid X receptor (RXR) and activates the expression of adipocyte-specific genes (FIG. 1a). Formaldehyde-assisted isolation of regulatory elements (FAIRE) sequencing analysis (see BOX 2 for technical terms) found that many of the PPAR $\gamma$ -binding sites at enhancer regions are enriched with H3K27 acetylation (H3K27ac) and H3K4me3 active enhancer marks that are associated with open chromatin<sup>32</sup>. These studies demonstrated that the introduction of specific histone modifications at the correct time during differentiation plays an important part in defining the adipocyte-selective gene programme driven by PPAR $\gamma$  and C/EBPs.

## Box 2

### Technical approaches and methods to study chromatin and transcription

Various experimental approaches have been developed to study epigenetic changes, recruitment of transcription regulators and 3D structure-based proximity of distal genes. Chromatin immunoprecipitation followed by deep sequencing (ChIP-seq) has been widely used to detect genome-wide distributions of a given transcription regulator.

Histone modifications can also be determined by ChIP-seq, using specific antibodies raised against particular modified histones. For the detection of open chromatin, several techniques, including DNase I hypersensitive assay (DHS assay), formaldehyde-assisted isolation of regulatory elements (FAIRE) and assay for transposase-accessible chromatin sequencing (ATAC-seq), have been developed. DHS assay is able to detect DNA accessibility (that is, open chromatin regions bound by transcriptional regulators by performing limited DNase digestion of isolated nuclei, followed by PCR or deep sequencing. FAIRE is a method to detect open chromatin structure (nucleosome-depleted DNA) on the basis of a difference in crosslinking efficiency between DNA and DNA-binding proteins. ATAC-seq utilizes an engineered Tn5 transposon that integrates primer DNA sequences, allowing for fragmentation of open chromatin regions.

Changes in 3D chromatin structure can be analysed by chromatin conformation capture (3C), which also serves as the basis for several derivative techniques, such as chromatin conformation capture sequencing (Hi-C), circular chromatin conformation capture sequencing (4C-seq), chromatin conformation capture carbon copy (5C) and chromatin interaction analysis by paired-end tag sequencing (ChIA-PET). These protocols involve crosslinking between DNA and transcriptional regulator protein complexes followed by chromatin isolation and fragmentation. Ligated DNA fragments are subsequently amplified by PCR (3C) or deep sequenced (Hi-C). The DNA fragments obtained are further self-circularized and sequenced (4C-seq) or amplified using ligation-mediated PCR (5C). In ChIA-PET, crosslinked and fragmented DNA-protein complexes are immunoprecipitated to identify specific interactions with a given protein.

As the factors discussed above are important for the specification of both WAT and BAT, how, then, are these two adipocyte lineages differentially established? Several lines of evidence indicate that the chromatin state (including histone marks and chromatin opening) is also distinct between white adipocytes and brown adipocytes. Approximately 55% of PPAR $\gamma$ -binding sites are overlapping among adipocytes from interscapular BAT, epididymal WAT and inguinal WAT<sup>33</sup>. Notably however, 10% of PPAR $\gamma$ -binding sites are found to be specific to BAT when genome-wide PPAR $\gamma$ -binding sites are compared between interscapular BAT and epididymal WAT depots<sup>34</sup>. These data indicate that the BAT-selective chromatin structure defines the BAT-selective recruitment of PPAR $\gamma$  and C/EBPs to their target gene loci and drives the BAT-selective gene transcriptional programme. Of note, BAT-selective genes (for example, *Ucp1*) are demarcated from common adipocyte genes (for example, *Pparg*), partly by H3K27me3 marks (FIG. 1b). The promoter region of *Ucp1* contains H3K4me3 marks and is activated in brown adipocytes, whereas it contains H3K27me3 and is repressed in white adipocytes<sup>35</sup>. H3K27me3 marks on the BAT-selective genes are gradually removed during brown adipocyte differentiation. By contrast, the *Pparg* gene locus contains monovalent H3K4me3 marks at the promoter region both in white and brown adipocytes<sup>28,35</sup>. A recent study further compared the chromatin histone marks between cultured white adipocytes and beige adipocytes that were derived from human multipotent adipose-derived stem (hMADS) cells in the process of browning induced by a synthetic PPAR $\gamma$  ligand, rosiglitazone. Interestingly, this study showed that a relatively small subset (less than 10%) of all PPAR $\gamma$ -binding sites are altered during the rosiglita-zone-

induced browning<sup>36</sup>. It is therefore conceivable that this relatively small change in the PPAR $\gamma$ -binding sites may be sufficient to form beige-selective superenhancers and the chromatin opening state.

In addition to histone modifications, three-dimensional (3D) chromatin conformation changes have a key role in the control of adipocyte-selective gene expression. For example, a long-range connection between the fat mass and obesity-associated (*FTO*) locus (which exhibits strong genetic association with human obesity) and the homeobox gene *IRX3* encoding a transcription factor that negatively regulates beige adipocyte differentiation is achieved by 3D chromatin conformation changes<sup>37,38</sup>. Although the *FTO* and *IRX3* genes are separated by megabases, *FTO* controls *IRX3* (and *IRX5*) expression. Notably, a sequence variant (rs1421085) with a T-to-C single-nucleotide substitution in the non-coding region of the *FTO* locus, which disrupts a binding motif for the transcriptional repressor ARID5B (AT-rich interactive domain-containing protein 5B), leads to transcriptional derepression of *IRX3* and *IRX5*, and thereby repression of beige adipocyte biogenesis. When this sequence variant is modified using CRISPR–Cas9-mediated genome editing, this phenotype can be reversed<sup>38</sup>. A recent study by chromatin conformation capture (3C; see BOX 2 for technical terms) also showed that a chromatin conformational change, mediated by a phosphorylated form of histone demethylase JMJD1A (also known as KDM3A), is required for an acute activation of *Ucp1* gene expression in brown adipocytes in response to cAMP stimuli (see below for details on the induction of the thermogenic programme)<sup>39</sup>.

Altogether, brown and beige adipogenesis is associated with the establishment of a cell type-specific chromatin landscape, which then regulates the transcriptional programme driving differentiation. Notably, it seems that only very specific loci are distinctively regulated on a chromatin level during BAT as compared to WAT development, indicating that the acquisition of brown adipose cell fate is subject to precise regulation.

## Regulation of brown adipogenesis

Development of classical brown adipocytes occurs through two phases: lineage commitment of precursors, followed by the differentiation from brown pre-adipocytes to mature brown adipocytes. In this section, we describe the major molecular players involved in activating the transcriptional programme controlling brown adipogenesis (FIG. 2a).

### Brown adipose cell fate commitment

During prenatal development, classical brown pre-adipocytes arise primarily from cells residing in the dermomyotome that express engrailed 1 (EN1), myogenic factor 5 (MYF5), and paired-box protein 7 (PAX7), and can also give rise to skeletal muscle<sup>19,40,41</sup> (however, it is possible that other cell subpopulations may also be able to give rise to brown adipocyte lineages). The brown adipocyte versus muscle fate determination occurs through the activation of a set of genes that controls brown pre-adipocyte fate commitment, and through stable silencing of the muscle-selective gene programme (FIG. 2a). For instance, early B cell factor 2 (EBF2), a factor enriched in brown pre-adipocytes, is expressed in a distinct cell population from the population expressing muscle-specific transcription factor MYOD (myoblast determination protein) within the somitic mesoderm of early-stage mouse

embryos (at embryonic day E12.5)<sup>42</sup>. Hence, it is likely that cell fate determination of brown pre-adipocyte versus myoblasts is already completed by mid-gestation. Ectopic expression of EBF2 in myoblasts induces brown adipogenesis, and EBF2 represses the expression of MYOD and another muscle-specific transcription factor, myogenin. EBF2 is abundantly expressed in adult human brown pre-adipocytes<sup>15</sup>, indicating that EBF2 also has an important role during brown pre-adipocyte determination in humans.

As indicated with the EBF2 example above, by mis-expressing key lineage determination factors, it is possible to induce a switch between brown adipogenesis and myogenesis. Such experiments have been used to delineate various factors responsible for brown adipocyte cell fate commitment (FIG. 2a). For instance, genetic deletion of histone methyltransferase EHMT1, a crucial enzymatic component of the PRDM16 complex, substantially impairs brown adipocyte differentiation but also leads to an ectopic activation of skeletal muscle-selective genes, including myogenin<sup>43</sup>. This gene silencing of the myogenic programme by EHMT1 is required for PRDM16 to initiate brown adipogenesis<sup>43</sup>. Of note, PRDM16 deletion in MYF5-positive precursors (including brown pre-adipocytes) does not affect embryonic BAT development, indicating the existence of compensatory factors<sup>44</sup>. One of these factors could be PRDM3 (also known as EVI1), a PRDM family member that has high homology with PRDM16, which also binds to EHMT1 and C/EBP $\beta$  and is able to activate PPAR $\gamma$  expression<sup>44,45</sup>. Given the severe impairment of BAT development in *Ehmt1*-knockout mice, it can be concluded that EHMT1 probably functions as an enzymatic 'engine' for both PRDM3 and PRDM16 complexes and is a major determinant of the brown adipose fate by silencing the myogenic gene programme and by activating the BAT gene programme. Another important regulator of cell fate in dermomyotome precursors is Ewing sarcoma (EWS), the genetic deletion of which causes an ectopic activation of muscle genes in BAT<sup>46</sup>. EWS and its binding partner Y-box binding protein 1 (YBX1) activate the expression of bone morphogenetic protein 7 (BMP7) in brown pre-adipocytes, thereby promoting BAT development. Similarly, TATA-binding protein associated factor 7L (TAF7L) also plays a part in the transcriptional switch of BAT versus muscle lineages by forming a complex with PPAR $\gamma$  and PRDM16 (together with transcription factor IID (TFIID), a key multiprotein complex in the initiation of RNA polymerase II (Pol II)-dependent transcription). Consistent with the developmental cascade of BAT versus muscle lineage commitment, loss of TAF7L causes an ectopic activation of muscle-selective genes in BAT and impairs BAT development<sup>47</sup>.

### Brown adipocyte differentiation

PPAR $\gamma$  and the C/EBPs are the major regulators of adipocyte cell fate, and their activation drives the expression of adipocyte-lineage specific genes. Despite the differences between BAT and WAT in their physiological functions and developmental origins, as discussed above, many of the transcription cascades, including PPAR $\gamma$  and the C/EBPs, are important both in white and brown adipocyte differentiation<sup>20,22,23</sup>. However, the expression and transcriptional activity of these factors are differentially regulated by external stimuli and cell type-selective regulators, and various regulators and regulatory mechanisms of brown adipocyte differentiation have been identified (FIG. 2a). For example, C/EBP $\beta$  is expressed at higher levels in BAT than in WAT, and it is robustly induced by cold exposure in



BAT<sup>17,48</sup>. C/EBP $\beta$  is also a major target of several transcriptional and epigenetic regulators of brown adipocyte development. One of these regulators is PLAC8 (placenta-specific gene 8 protein), which is a Cys-rich protein that directly binds to the regulatory region of the gene encoding C/EBP $\beta$  and activates its transcription, thereby promoting brown fat differentiation<sup>49</sup>. On the other hand, microRNA miR-155 represses C/EBP $\beta$  expression and impairs brown adipocyte differentiation<sup>50</sup>. Another microRNA, miR-196a, promotes brown adipocyte differentiation by repressing *HoxC8* (homeobox C8), which negatively regulates C/EBP $\beta$  by recruiting histone deacetylase 3 (HDAC3) on the 3' untranslated region (UTR) of *Cebpb*<sup>51</sup>, which then represses *Cebpb* transcription. Similarly, several co-regulators control brown adipogenesis through regulating the transcriptional activity of PPAR $\gamma$ . The acetyltransferase GCN5 (also known as KAT2A) and its homologue P300/CBP-associated factor (PCAF; also known as KAT2B) are required for brown adipogenesis, as they control transcription elongation during PPAR $\gamma$  expression and modulate Pol II recruitment to activate PRDM16 expression<sup>52</sup>. As described earlier, PRDM16 forms a transcriptional complex with C/EBP $\beta$  and PPAR $\gamma$  to powerfully promote brown adipogenesis<sup>17,19</sup>. EBF2 also promotes brown adipogenesis by recruiting PPAR $\gamma$  to its BAT-selective binding sites<sup>34</sup>. In addition, myeloid/lymphoid or mixed-lineage leukaemia 4 (MLL4; also known as KMT2D), a H3K4 mono- and dimethyltransferase, colocalizes with C/EBP $\beta$  and PPAR $\gamma$  to further stimulate the expression of genes regulated by these transcription factors, thereby promoting brown adipogenesis<sup>53</sup>. Recent studies also identified a zinc-finger protein, ZFP516, as an interacting partner of PRDM16, which promotes brown adipogenesis and thermogenesis<sup>54</sup>. Finally, transducin-like enhancer protein 3 (TLE3), a member of the Groucho family of transcriptional co-repressors, has been shown to antagonize PRDM16 and inhibit its action during brown adipogenesis by competing for its interaction with PPAR $\gamma$ <sup>55</sup>.

## Regulation of beige adipogenesis

Although much less is known regarding the cellular lineage specification of beige adipocytes as compared to classical brown adipocytes, it is clear that brown and beige adipocytes arise from distinct developmental lineages. Classical brown adipocytes are prenatally derived from a population of MYF5<sup>+</sup> dermatomes, whereas beige adipocytes emerge postnatally from a pre-adipocyte population positive for platelet-derived growth factor receptor- $\alpha$  (PDGFR $\alpha$ <sup>+</sup>) and stem cells antigen 1 (SCA1<sup>+</sup>), or from smooth muscle-like precursors positive for myosin heavy chain 11 (MYH11<sup>+</sup>), and their emergence occurs in response to a variety of internal or external stimuli, including chronic cold exposure, PPAR $\gamma$  agonists, cancer cachexia, exercise and several endocrine hormones (reviewed in REF. 12). However, many of the currently identified transcriptional and epigenetic regulators have similar roles both in brown and beige adipocyte development (FIG. 2a,b). For instance, EBF2 is highly expressed in the PDGFR $\alpha$ <sup>+</sup> populations and promotes beige adipocytes in mouse inguinal WAT depots<sup>42,56</sup>. PRDM16 expression in white pre-adipocytes also potently activates a number of beige-selective genes and induces beige adipocyte biogenesis<sup>57</sup>, whereas depletion of PRDM16 substantially impairs beige adipocyte development<sup>58,59</sup>. Of note, PRDM16 promotes beige adipocyte differentiation by functioning as an activator of the beige fat gene programme and a repressor of WAT-selective genes such as resistin. This

repressive effect of PRDM16 on WAT-enriched genes occurs through a direct interaction between PRDM16 and carboxy-terminal binding proteins (CtBP1 and CtBP2)<sup>60</sup>, which form a transcriptional repressor complex with PRDM16 and silences the WAT-selective genes. On the other hand, adipose-specific loss of retinoblastoma-like protein 1 (also known as p107), which antagonizes PRDM16 action or loss of TLE3, promotes beige adipocyte development *in vivo*<sup>55,61</sup>. Additionally, forkhead box protein C2 (FOXC2) expression promotes beige adipocyte biogenesis by upregulating the RI $\alpha$  subunit of protein kinase A (PKA)<sup>62</sup>, which is a major downstream kinase activated by  $\beta$ -adrenergic receptor ( $\beta$ -AR) signalling (see the section on the regulation of adipocyte thermogenesis).

There are also a few examples of factors that are selectively involved in beige adipogenesis without affecting classical brown adipocyte development (TABLE 1). One such example is myocardin-related transcription factor A (MRTFA), which is a globular actin (G-actin)-regulated transcriptional co-regulator of serum response factor (SRF)<sup>63</sup>. The SRF–MRTFA transcriptional regulator complex is under the control of BMP7 (which also influences brown adipocyte cell fate commitment, as discussed above). Upon BMP7 treatment, the SRF–MRTFA complex is repressed, and this allows beige adipocyte differentiation. Genetic loss of MRTFA selectively promotes beige adipocyte biogenesis in WAT without affecting interscapular BAT. Conversely, overexpression of SRF or MRTFA inhibits beige adipocyte differentiation and induces smooth muscle differentiation in cultured mesenchymal cells<sup>63</sup>. Given the recent finding that some beige adipocytes are derived from smooth muscle-like precursors<sup>64</sup>, SRF–MRTFA may control cell fate decisions between smooth muscle and beige adipocyte lineages. In contrast to BMP7, another signalling molecule, transforming growth factor- $\beta$  (TGF $\beta$ ) inhibits beige adipocyte differentiation and promotes smooth muscle-like differentiation. In line with this, genetic loss of SMAD3, a key mediator of TGF $\beta$ , or blockade of SMAD3 signalling by a neutralizing antibody against the activin receptor type IIB (ActRIIB), preferentially promotes beige adipocyte development<sup>65,66</sup>. As another example of beige-selective regulators, Krüppel-like factor 11 (KLF11) is induced in response to rosiglitazone treatment and selectively activates beige adipocyte-selective gene expression by maintaining the association of PPAR $\gamma$  with superenhancers of beige-selective genes<sup>36</sup>. It has also been shown that transcriptional repressor HES1, which is activated by Notch signal reception, represses *Prdm16* and *Pgc1a* gene expression during beige adipogenesis by directly binding to their proximal promoter regions. This effect seems to be specific to beige adipocytes, as inhibition of Notch signalling by deletion of *Hes1* selectively induces beige adipocyte biogenesis without affecting classical brown adipocyte development<sup>67</sup>.

It is worth pointing out that each WAT depot possesses a different susceptibility to undergo browning. Cold exposure or chronic treatment with synthetic ligands of PPAR $\gamma$  (see below, under external cues regulating browning of WAT) strongly promotes beige adipocyte differentiation in subcutaneous WAT, whereas the browning effect is much more modest in visceral WAT<sup>58,68</sup>. This difference seems to be largely cell-autonomous, as much higher levels of browning can be achieved in cultured inguinal WAT-derived primary adipocytes as compared to epididymal-WAT derived adipocytes from identical mice<sup>58</sup>. Although high levels of PRDM16 have been shown to control a part of high browning propensity in inguinal WAT<sup>57</sup>, ectopic expression of PRDM16 in visceral WAT is not sufficient to fully

reprogramme the browning susceptibility to match that of the inguinal WAT<sup>58</sup>. At least in the context of browning induced by synthetic PPAR $\gamma$  ligands, it is possible that the cell-autonomous browning propensity depends, at least in part, on the differential chromatin opening on beige-selective gene promoters and/or enhancers in cells originating from different WAT depots, which would then differentially regulate the accessibility of PPAR $\gamma$  to its target genes.

## Regulation of adipocyte thermogenesis

A unique feature of brown and beige adipocytes is their thermogenic function, which greatly depends on the expression and function of the BAT-specific mitochondrial protein UCP1. Studies to date have centred primarily on the regulatory mechanisms governing *Ucp1* transcription<sup>69–71</sup> (however, thermogenic transcriptional programmes are also responsible for the increase in the uptake of glucose and fatty acids, as well as enhanced uncoupling of mitochondrial respiration, leading to energy dissipation). The transcriptional network involved in the regulation of the thermogenic programme is depicted in FIG. 3a.

The thermogenic programme is triggered by cold stimuli and is largely (but not entirely) initiated by the activation of  $\beta$ -AR signalling (reviewed in REF. 72; see also the following section). The activated  $\beta$ -ARs increase intracellular levels of cAMP, which is followed by the activation of CREB (cAMP-responsive element-binding) and ATF2 transcription factors through their phosphorylation by PKA, leading to direct activation of *Ucp1* and *Pgc1a* transcription by these factors<sup>70</sup>. PPAR $\gamma$  and C/EBP $\beta$  are also known to directly activate *Ucp1* and *Pgc1a* transcription<sup>17,19,73</sup>. Adipose-selective transgenic expression of FOXC2 increases intracellular cAMP levels by increasing the expression of PKA (the RI $\alpha$  subunit) and promotes beige adipocyte thermogenesis in WAT<sup>62</sup>. By contrast, histone deacetylase HDAC1 (and HDAC2) inhibits thermogenesis through deacetylation of H3K27 on the regulatory regions of *Ucp1*, which then inhibits CREB and ATF2 mediated transcription<sup>74</sup>. Intriguingly it has been recently found that casein kinase 2 (CK2) activity in response to  $\beta$ -AR signalling is preferentially increased in WAT and inhibits the thermogenic programme in this tissue. Genetic or pharmacological inhibition of CK2 in white adipocytes promotes cAMP-induced thermogenesis, and this is mediated in part by lack of the stimulatory effect of CK2 on class I HDAC activity<sup>75</sup>. Additionally,  $\beta$ -AR signalling resulting from cold exposure activates histone demethylase JMJD1A, which, as discussed in more detail in the section below, promotes efficient transcription mediated by PPAR $\gamma$ <sup>39</sup>.

PGC1 $\alpha$  is a transcriptional co-activator that has a central role in controlling the cold-induced thermogenesis gene programme in differentiated brown and beige adipocytes<sup>76,77</sup>. PGC1 $\alpha$  expression is highly induced in response to cold exposure followed by cAMP signalling, and it activates a number of thermogenic genes by interacting with various transcriptional regulators. For instance, thyroid hormone receptor, after binding its ligand triiodothyronine (T3), activates *Ucp1* transcription through forming an activator complex with PGC1 $\alpha$ , PRDM16 and Mediator complex subunit 1 (MED1)<sup>78,79</sup>. Interferon regulatory factor 4 (IRF4) is activated by cAMP stimuli and interacts with PGC1 $\alpha$  in brown adipocytes. The IRF4–PGC1 $\alpha$  complex is recruited to the regulatory regions of the *Ucp1* gene locus to activate its transcription<sup>80</sup>. As described above, PRDM16 directly interacts with PGC1 $\alpha$  and

induces its transcriptional activity<sup>18</sup>. On the other hand, various proteins have been identified as negative regulators of PGC1 $\alpha$  transcription or its activity. Receptor-interacting protein 140 (RIP140; also known as NRIP1) directly binds to PGC1 $\alpha$  and represses its transcriptional activity<sup>81</sup>. Liver X receptor (LXR) interacts with RIP140 to dismiss the PGC1–PPAR $\gamma$  recruitment<sup>82</sup>. SRC2 (also known as TIF2 or GRIP1), a member of the steroid receptor co-activator family, and a helix–loop–helix-containing transcriptional regulator TWIST 1 (Twist-related protein 1) also repress PGC1 $\alpha$  transcriptional activity by directly binding to PGC1 $\alpha$ <sup>83,84</sup>. Similarly, retinoblastoma protein (Rb) and p107 negatively regulate PGC1 $\alpha$  gene expression<sup>61,85</sup>. Genetic loss of these negative regulators (SRC2, TWIST1, RIP140, Rb and p107) induces thermogenic gene expression and adipose thermogenesis<sup>61,83–88</sup>. As described above, PGC1 $\alpha$  is an essential transcriptional co-activator of BAT thermogenesis; however, brown adipogenesis and BAT mass are not affected by the genetic loss of PGC1 $\alpha$ <sup>89,90</sup>, indicating that PGC1 $\alpha$  is dispensable for the fate determination of brown adipocytes.

In addition to PGC1 $\alpha$ , it has been shown that ZFP516 functions as a transcriptional regulator of thermogenesis. ZFP516 is induced by cold, and, after forming a complex with PRDM16, it is recruited to the *Ucp1* and *Pgc1a* gene loci and activates their expression, thereby promoting thermogenesis<sup>54</sup>. Moreover, C/EBP $\beta$ , as well as controlling white and brown adipogenesis, stimulates the transcription of cAMP-induced thermogenic genes (for example, *Ucp1* and *Pgc1a*) by forming a PRDM16 transcriptional complex<sup>17,48</sup>.

## Regulation by external cues

As well as intricate transcriptional networks, various external stimuli control brown and beige adipose tissue cell fate determination, maintenance and thermogenic function. This is particularly relevant for beige adipocytes, given the inducible characteristics of beige adipogenesis. As biogenesis of beige adipocytes bears strong relevance to the physiology of adult humans, it is particularly important to understand the molecular mechanisms by which external cues are integrated into chromatin state and how they control beige adipocyte development and functionality through a set of transcriptional and epigenetic machineries.

Among the many reported external cues (reviewed in REF. 12), here we primarily focus on the transcriptional mechanisms by which the brown and beige adipocyte thermogenic programme is regulated by cold-induced cAMP signalling. We then discuss how synthetic PPAR $\gamma$  ligands promote beige adipocyte biogenesis. In addition, we discuss possible roles of metabolites in adipocyte development, with a special emphasis on their roles as cofactors for epigenetic regulators.

## Cold exposure

Cold is a potent stimulus of thermogenesis in brown and beige adipocytes. Under cold exposure, catecholamine is released from sympathetic nerve endings. Secreted catecholamine binds to  $\beta$ -AR on the cell surface adipocytes and subsequently enhances the interaction of the receptor with guanine nucleotide-binding protein (G protein), which in turn activates adenylyl cyclase to increase intercellular cAMP concentration (FIG. 3b). cAMP stimulates PKA and p38 MAPK (reviewed in REF. 72). P38 MAPK can also be

activated by cardiac natriuretic peptides, such as atrial and ventricular natriuretic peptides released upon cold exposure. These peptides act through guanylyl cyclase-coupled receptors, inducing cGMP–protein kinase G (PKG) signalling in brown adipocytes<sup>91</sup> (FIG. 3b). Activated p38 MAPK phosphorylates ATF2, which, as discussed above, directly triggers the transcription of *Ucp1* and *Pgc1a*<sup>70</sup>. Besides the PKA–p38 MAPK signalling pathway, a recent study used phosphoproteomics in brown, beige and white adipocytes to identify previously unappreciated kinases, such as CK2, that are differentially regulated in a cell type-selective fashion in response to another  $\beta$ -AR agonist, noradrenaline<sup>75</sup>.

Additionally, the enhancer–promoter proximity of thermogenic genes in brown adipocytes is dynamically regulated by cold (and cold stimulus-associated hormones). It has been demonstrated that PRDM16 alters the enhancer–promoter proximity by binding to and recruiting MED1 to the *Ucp1* and *Pgc1a* gene loci<sup>26,78</sup>. In addition, JMJD1A is phosphorylated at S265 in response to cAMP signalling via PKA<sup>39</sup> (FIG. 3b). The phosphorylated JMJD1A forms a transcriptional complex with the SWI/SNF chromatin remodeller and is recruited to the PPAR response elements of the thermogenic genes (for example, *Ucp1* and *Adrb1* (adrenoceptor- $\beta$ 1)). This recruitment induces demethylation of H3K9me2 and allows transcription factor-bound enhancers and thermogenic gene promoters to be brought into close proximity<sup>39</sup>. Intriguingly, the change in the JMJD1A-initiated promoter–enhancer proximity has been shown to occur within minutes and peaked 60 minutes after cAMP stimuli<sup>39</sup>. As covalent histone marks are generally more stable than protein phosphorylation, it is conceivable that cold-induced chromatin remodelling, as triggered by JMJD1A phosphorylation, serves as an ‘epigenetic memory’ that allows for rapid activation of thermogenic gene expression in response to a future bout of cold exposure.

### PPAR $\gamma$ agonist treatment and PRDM16 protein stabilization

Chronic treatment with a synthetic ligand of PPAR $\gamma$ , such as thiazolidinedione (TZD), strongly induces browning of WAT<sup>58,92–98</sup>. It was considered for a long time that such induction occurred simply by direct binding of ligand-activated PPAR $\gamma$  on the PPAR response elements on the regulatory regions of beige-selective genes<sup>98–100</sup>. However, this explanation is insufficient to explain in full the mechanism of TZD-induced browning, for the following two reasons. First, PPAR $\gamma$  is abundantly expressed both in WAT and BAT, and it is required for the formation of both cell types<sup>22,23</sup>; additionally, over-expression of PPAR $\gamma$  in white adipocytes does not induce WAT browning<sup>101</sup>, whereas transactivation of PPAR $\gamma$  by synthetic ligands can do so. Second, chronic treatment with PPAR $\gamma$  ligands, at least for 3 days or longer, is required for the WAT browning effect<sup>58</sup>. The slow kinetics of PPAR $\gamma$  ligands are not consistent with a direct activation through the PPAR response elements, which can occur within 10 minutes of TZD treatment<sup>102</sup>. This implies the involvement of an alternative molecular mechanism of TZD-induced WAT browning.

It has been reported that PRDM16 in subcutaneous WAT is required for TZD-induced WAT browning<sup>58</sup>. Intriguingly, treatment with rosiglitazone, one of the members of the TZD class, stabilizes PRDM16 protein (without affecting *PRDM16* mRNA transcription) and extends its half-life from 5.9 hours to 17.5 hours<sup>58</sup>. This PRDM16 protein stabilization model

explains well the slow kinetics of the TZD-induced browning, as three-day treatment with TZD can lead to the accumulation of PRDM16 protein by approximately 250-fold. In addition, TZD treatment has been shown to induce sirtuin 1 (SIRT1)-dependent deacetylation of PPAR $\gamma$ , which then enhances the formation of PRDM16 and PPAR $\gamma$  complex, further promoting WAT browning<sup>103</sup>. Furthermore, KLF11 is induced by TZD treatment and, as discussed above, cooperates with PPAR $\gamma$  to maintain the beige-selective histone modification in human white adipocytes<sup>36</sup> (FIG. 3c).

TZDs are pharmacological agents and may not necessarily well reflect physiological cues. However, it has recently been found that capsinoids (non-pungent analogues of capsaicin), through an activation of  $\beta$ 2-AR, also induce WAT browning and PRDM16 protein stabilization in subcutaneous WAT<sup>104</sup>. It is conceivable that other hormonal stimuli — such as BMP7 (REFS 105,106), a newly identified myokine, irisin<sup>107</sup>, fibroblast growth factor 21 (FGF21)<sup>108,109</sup> and natriuretic peptides<sup>91</sup> — may also induce WAT browning through this mechanism. The molecular mechanism by which chronic treatment with TZDs and capsinoids induces PRDM16 protein stabilization remains unknown. It is known, however, that PRDM16 stability is highly regulated by the ubiquitin–proteasome pathway, and therefore it is highly likely that deubiquitylation is the underlying mechanism responsible for the enhanced stabilization of PRDM16 (FIG. 3c). Although specific E3 ubiquitin-ligases for PRDM16 have not yet been identified, it is possible that the specific E3-ligases for PRDM16, once delineated, may serve as a plausible pharmacological target to induce the WAT browning without activating PPAR $\gamma$  transcriptional activity.

In addition to transcriptional activation of the beige adipocyte-specific programme, TZDs also repress WAT-selective genes in white adipocytes, as well as pro-inflammatory genes in macrophages. It has been shown that the repression of WAT-selective genes by TZDs requires C/EBP $\alpha$  and the recruitment of CtBP1 and CtBP2 on the promoter of the repressed genes<sup>97</sup>. In macrophages, the repression of inflammatory responses by PPAR $\gamma$  is achieved through ligand-dependent sumoylation of PPAR $\gamma$ , which promotes the recruitment of the PPAR $\gamma$ –nuclear receptor co-repressor (NCoR)–HDAC3 repressor complex to nuclear factor- $\kappa$ B (NF- $\kappa$ B) target gene promoters, resulting in their *trans*-repression<sup>110,111</sup>. A recent study proposed yet another mechanism of rosiglitazone-mediated transcriptional repression. In this study, enhancer transcription (that is, the synthesis of so-called enhancer RNAs (eRNAs)) in adipocytes was analysed<sup>102</sup>. It has been shown that rosiglitazone-induced activation of eRNA transcripts occurs at promoters and enhancers containing PPAR $\gamma$ -binding motifs and is largely mediated by the robust recruitment of co-activator complexes (including Mediator and p300–CREB-binding protein (CBP) complexes). At the same time, eRNA synthesis was downregulated at enhancers in the vicinity of genes not associated with PPAR $\gamma$  (but enriched for binding motifs of other transcriptional regulators such as AP1 and C/EBPs). It has been concluded that rosiglitazone-mediated repression results from the redistribution of co-activator complexes to sites strongly associated with PPAR $\gamma$ , thereby limiting the available co-activators that could function at sites bound by other transcription factors such as AP1 and C/EBPs.

## Roles of metabolites

Several lines of evidence indicate that quantitative changes in levels of intracellular metabolites modulate the chromatin landscape (reviewed in REF. 112). For instance, NAD<sup>+</sup> is an essential cofactor for NAD<sup>+</sup>-dependent histone deacetylases (sirtuins). Moreover,  $\alpha$ -ketoglutarate ( $\alpha$ KG), which is a metabolite of the tricarboxylic acid (TCA) cycle and glutamine metabolism, is a crucial co-factor for histone and DNA demethylases, such as JMJD histone demethylases and 5-methylcytosine hydroxylases (also known as TETs) (FIG. 4). In fact,  $\alpha$ KG has been shown to maintain ES cell pluripotency by controlling H3K27me3 and DNA methylation<sup>113</sup>.  $\alpha$ KG is mainly produced from isocitrate in the TCA cycle, in which the NAD(P)<sup>+</sup>-dependent isocitrate dehydrogenases (IDH1 and IDH2) have key roles. When the *IDH* genes are mutated (as is frequently seen in several types of cancer cells), the mutant IDH produces 2-hydroxyglutarate (2HG) from  $\alpha$ KG, which inhibits  $\alpha$ KG-dependent enzymes such as JMJDs and TETs (FIG. 4). It is reported that mutation in the IDH2 is associated with elevated H3K9me3 and H3K27me3 levels at the promoter regions of *Pparg* and *Cebpa* in 3T3-L1 cells, leading to an inhibition of adipogenesis<sup>114</sup>. As another example, the glycolysis-derived metabolite acetyl-CoA, which can serve as a donor for histone acetylation, also controls differentiation of 3T3-L1 pre-adipocytes and ES cells by modulating histone acetylase activity<sup>115,116</sup>.

What are the physiological implications of the metabolite-mediated epigenetic changes in adipose tissues? Although it is still a matter of speculation, a subtle change in intercellular metabolite concentrations may control differentiation or the thermogenic function of brown and beige fat. Reduced  $\alpha$ KG levels may modulate JMJD and TET activities, thereby inducing hypermethylation (H3K9me3, H3K27me3 or DNA methylation) of their target genes. Given the role of JMJDs in the regulation of thermogenic gene expression, it is likely that a reduced concentration of  $\alpha$ KG leads to a suppression of the BAT-selective gene programme and of thermogenic capability. As various metabolites are known to modulate epigenetic modifiers (FIG. 4), it would be now intriguing to examine the extent to which an alteration in intracellular metabolite levels affects adipocyte development and thermogenesis.

## Conclusions and future perspectives

Brown and beige adipocyte development and thermogenic function rely greatly on the activation of brown and beige adipocyte-specific gene programmes that are coordinately regulated by adipose-selective chromatin architectures and by a set of unique transcriptional and epigenetic regulators. As discussed above, some of the transcriptional and epigenetic regulators, including PRDM16 and histone demethylases, are also required for establishing chromatin structures and regulating gene transcription to promote beige adipocyte biogenesis in response to various environmental stimuli.

A better understanding is now needed regarding the spatiotemporal regulation of chromatin conformation and transcriptional complex recruitment. It would be particularly compelling to unravel how these changes on the level of chromatin are induced and regulated in response to external stimuli. As discussed earlier, the cold-induced phosphorylation of JMJD1A changes the enhancer–promoter proximity of BAT-selective thermogenic genes by

forming a long-range chromatin loop with the SWI/SNF complex<sup>39</sup>. Another example is a functional long-range connection between the homeobox gene *IRX3* and the enhancer region of the *FTO* locus<sup>37,38</sup>. These studies suggest that locus-specific changes in 3D chromatin conformation are crucial for the establishment and maintenance of the beige-selective enhancers and promoters in response to a given cue. To this end, high-resolution chromatin conformation capture sequencing (Hi-C) or chromatin interaction analysis with paired-end tag sequencing (ChIA-PET; see BOX 2 for technical terms) may be useful to understand the genome-wide chromatin conformational changes.

Given the high cellular heterogeneity within adipose tissues, it is crucial to characterize the molecular signatures and chromatin structures of adipocytes, especially beige adipocytes, at the single-cell level resolution. By combining the CRISPR-Cas9-based DNA methylation reporter system and bisulfite sequencing, a recent study described time course changes in *de novo* DNA methylation at the promoter and superenhancers in single mouse ES cells<sup>117</sup>. Combined with single-cell RNA sequencing technology, single-cell resolution analyses would be useful to understand cellular heterogeneity within adipose tissues and further examine the epigenetic changes that control the cell-autonomous browning susceptibility.

## Acknowledgments

The authors apologize for their inability to cite many papers that contributed to the advancement of this field, owing to a space limit. S.K. is supported by the US National Institutes of Health (NIH; DK97441 and DK108822), the Pew Charitable Trust and the Japan Science and Technology Agency. T.I. and J.S. are supported by grants-in-aid for scientific research (B, 25291002 and S, 22229009) and the translational systems biology and medicine initiative (TSBMI) from the Ministry of Education, Science, Sports and Culture (MEXT), Japan. The authors thank Yoshihiro Matsumura for critical reading of the manuscript.

## Glossary

### **Interscapular BAT**

Brown adipose tissue (BAT) is a specialized organ that produces heat. BAT is localized in the interscapular and perirenal regions of rodents and infants

### **Myoblasts**

Myogenic progenitor cells that differentiate into myocytes (muscle cells)

### **Transcriptional co-regulator**

Transcriptional regulator that acts through forming a complex with DNA-binding transcriptional factors

### **Pioneer factors**

Transcription factors that can access their target genomic sites in closed chromatin. Pioneer factors trigger enhancer competency and control cell fate determination

### **Retinoid X receptor (RXR)**

A nuclear receptor that heterodimerizes with other nuclear receptors, including peroxisome proliferator-activated receptors (PPARs). Endogenous ligands remain unknown

### **Epididymal WAT and inguinal WAT**



Inguinal white adipose tissue (WAT) is a major subcutaneous WAT depot in rodents. Epididymal WAT is a visceral WAT

#### **Human multipotent adipose-derived stem (hMADS) cells**

Cells derived from the prepubic fat pad of a 4-month-old male donor. hMADS cells differentiate to white adipocytes using an adipogenic cocktail, and also to beige adipocytes as a result of chronic treatment with synthetic peroxisome proliferator-activated receptor (PPAR) agonists such as rosiglitazone

#### **Superenhancers**

Enhancer domains that are densely occupied with transcriptional regulators and mediator complexes. Superenhancers have key roles in regulating expression of genes essential for cell fate

#### **Somitic mesoderm**

Mesodermal tissue, which in vertebrate embryos forms in concert with the neural tube during neurulation. This area develops into somites that give rise to skeletal muscle, bone, connective tissues and skin

#### **Cancer cachexia**

A wasting syndrome that leads to body weight loss and atrophy of WAT and skeletal muscle in response to a malignant growth

#### **Resistin**

A Cys-rich secreted peptide from adipocytes that is associated with obesity and diabetes

#### **Mediator complex subunit 1 (MED1)**

A core component of the Mediator complex that functions as a transcriptional co-activator. MED1 associates with general transcription factors and RNA polymerase II and has an essential role in activator-dependent transcription in all eukaryotes

#### **Irisin**

A secreted peptide from skeletal muscle (that is, a myokine) that regulates browning of WAT and thermogenesis

#### **Nuclear receptor co-repressor (NCoR)**

A transcriptional repressor that recruits histone deacetylases to the regulatory elements of its target genes and represses their transcription

## **References**

1. Sidossis L, Kajimura S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. *J Clin Invest.* 2015; 125:478–486. [PubMed: 25642708]
2. Cypess AM, et al. Identification and importance of brown adipose tissue in adult humans. *N Engl J Med.* 2009; 360:1509–1517. [PubMed: 19357406]
3. Ouellet V, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of 18F-FDG-detected BAT in humans. *J Clin Endocrinol Metab.* 2011; 96:192–199. [PubMed: 20943785]

4. van Marken Lichtenbelt WD, et al. Cold-activated brown adipose tissue in healthy men. *N Engl J Med.* 2009; 360:1500–1508. [PubMed: 19357405]
5. Saito M, et al. High incidence of metabolically active brown adipose tissue in healthy adult humans: effects of cold exposure and adiposity. *Diabetes.* 2009; 58:1526–1531. [PubMed: 19401428]
6. Yoneshiro T, et al. Recruited brown adipose tissue as an antiobesity agent in humans. *J Clin Invest.* 2013; 123:3404–3408. [PubMed: 23867622]
7. van der Lans AA, et al. Cold acclimation recruits human brown fat and increases nonshivering thermogenesis. *J Clin Invest.* 2013; 123:3395–3403. [PubMed: 23867626]
8. Lee P, et al. Temperature-acclimated brown adipose tissue modulates insulin sensitivity in humans. *Diabetes.* 2014; 63:3686–3698. [PubMed: 24954193]
9. Hanssen MJ, et al. Short-term cold acclimation improves insulin sensitivity in patients with type 2 diabetes mellitus. *Nat Med.* 2015; 21:863–865. [PubMed: 26147760]
10. Heaton JM. The distribution of brown adipose tissue in the human. *J Anat.* 1972; 112:35–39. [PubMed: 5086212]
11. Lidell ME, et al. Evidence for two types of brown adipose tissue in humans. *Nat Med.* 2013; 19:631–634. [PubMed: 23603813]
12. Kajimura S, Spiegelman BM, Seale P. Brown and beige fat: physiological roles beyond heat generation. *Cell Metab.* 2015; 22:546–559. [PubMed: 26445512]
13. Wu J, et al. Beige adipocytes are a distinct type of thermogenic fat cell in mouse and human. *Cell.* 2012; 150:366–376. [PubMed: 22796012]
14. Sharp LZ, et al. Human BAT possesses molecular signatures that resemble beige/brite cells. *PLoS ONE.* 2012; 7:e49452. [PubMed: 23166672]
15. Shinoda K, et al. Genetic and functional characterization of clonally derived adult human brown adipocytes. *Nat Med.* 2015; 21:389–394. [PubMed: 25774848]
16. Min SY, et al. Human ‘brite/beige’ adipocytes develop from capillary networks, and their implantation improves metabolic homeostasis in mice. *Nat Med.* 2016; 22:312–318. [PubMed: 26808348]
17. Kajimura S, et al. Initiation of myoblast to brown fat switch by a PRDM16-C/EBP- $\beta$  transcriptional complex. *Nature.* 2009; 460:1154–1158. This paper reports the generation of thermogenic BAT from non-adipogenic cells *in vivo*. [PubMed: 19641492]
18. Seale P, et al. Transcriptional control of brown fat determination by PRDM16. *Cell Metab.* 2007; 6:38–54. This paper reports the identification of PRDM16, the master regulator of brown adipocyte development. [PubMed: 17618855]
19. Seale P, et al. PRDM16 controls a brown fat/skeletal muscle switch. *Nature.* 2008; 454:961–967. [PubMed: 18719582]
20. Rosen ED, Spiegelman BM. What we talk about when we talk about fat. *Cell.* 2014; 156:20–44. [PubMed: 24439368]
21. Kajimura S, Seale P, Spiegelman BM. Transcriptional control of brown fat development. *Cell Metab.* 2010; 11:257–262. [PubMed: 20374957]
22. Rosen ED, et al. PPAR $\gamma$  is required for the differentiation of adipose tissue *in vivo* and *in vitro*. *Mol Cell.* 1999; 4:611–617. [PubMed: 10549292]
23. Barak Y, et al. PPAR $\gamma$  is required for placental, cardiac, and adipose tissue development. *Mol Cell.* 1999; 4:585–595. [PubMed: 10549290]
24. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR $\gamma$ 2, a lipid-activated transcription factor. *Cell.* 1994; 79:1147–1156. [PubMed: 8001151]
25. Nishikata I, et al. A novel *EVII* gene family, *MELI*, lacking a PR domain (*MELIS*) is expressed mainly in t(1;3)(p36;q21)-positive AML and blocks G-CSF-induced myeloid differentiation. *Blood.* 2003; 102:3323–3332. [PubMed: 12816872]
26. Harms MJ, et al. PRDM16 binds MED1 and controls chromatin architecture to determine a brown fat transcriptional program. *Genes Dev.* 2015; 29:298–307. [PubMed: 25644604]
27. Lefterova MI, et al. PPAR $\gamma$  and C/EBP factors orchestrate adipocyte biology via adjacent binding on a genome-wide scale. *Genes Dev.* 2008; 22:2941–2952. This is the first paper to report the genome-wide analysis of transcription factors during adipogenesis. [PubMed: 18981473]

28. Mikkelsen TS, et al. Comparative epigenomic analysis of murine and human adipogenesis. *Cell*. 2010; 143:156–169. This paper reports a comprehensive genome-wide epigenetic analysis in human and mouse adipocytes. [PubMed: 20887899]
29. Lefterova MI, et al. Cell-specific determinants of peroxisome proliferator-activated receptor  $\gamma$  function in adipocytes and macrophages. *Mol Cell Biol*. 2010; 30:2078–2089. [PubMed: 20176806]
30. Matsumura Y, et al. H3K4/H3K9me3 bivalent chromatin domains targeted by lineage-specific DNA methylation pauses adipocyte differentiation. *Mol Cell*. 2015; 60:584–596. [PubMed: 26590716]
31. Siersbaek R, et al. Extensive chromatin remodelling and establishment of transcription factor ‘hotspots’ during early adipogenesis. *EMBO J*. 2011; 30:1459–1472. [PubMed: 21427703]
32. Waki H, et al. Global mapping of cell type-specific open chromatin by FAIRE-seq reveals the regulatory role of the NFI family in adipocyte differentiation. *PLoS Genet*. 2011; 7:e1002311. [PubMed: 22028663]
33. Siersbaek MS, et al. Genome-wide profiling of peroxisome proliferator-activated receptor  $\gamma$  in primary epididymal, inguinal, and brown adipocytes reveals depot-selective binding correlated with gene expression. *Mol Cell Biol*. 2012; 32:3452–3463. [PubMed: 22733994]
34. Rajakumari S, et al. EBF2 determines and maintains brown adipocyte identity. *Cell Metab*. 2013; 17:562–574. [PubMed: 23499423]
35. Pan D, et al. Jmjd3-mediated H3K27me3 dynamics orchestrate brown fat development and regulate white fat plasticity. *Dev Cell*. 2015; 35:568–583. This study reports the importance of repressive H3K27me3 marks in regulating BAT-selective gene expression. [PubMed: 26625958]
36. Loft A, et al. Browning of human adipocytes requires KLF11 and reprogramming of PPAR $\gamma$  superenhancers. *Genes Dev*. 2015; 29:7–22. This study describes genome-wide changes in chromatin structure and promoter–enhancers during the browning of white adipocytes. [PubMed: 25504365]
37. Smemo S, et al. Obesity-associated variants within FTO form long-range functional connections with *IRX3*. *Nature*. 2014; 507:371–375. [PubMed: 24646999]
38. Claussnitzer M, et al. FTO obesity variant circuitry and adipocyte browning in humans. *N Engl J Med*. 2015; 373:895–907. This paper describes the long-range functional interaction between non-coding sequences within the *FTO* locus and *IRX3* to regulate beige fat thermogenesis and obesity. [PubMed: 26287746]
39. Abe Y, et al. JMJD1A is a signal-sensing scaffold that regulates acute chromatin dynamics via SWI/SNF association for thermogenesis. *Nat Commun*. 2015; 6:7052. This study describes a mechanism by which a conformational change in chromatin structure controls thermogenic gene expression through phosphorylation of histone demethylase JMJD1A. [PubMed: 25948511]
40. Lepper C, Fan CM. Inducible lineage tracing of Pax7-descendant cells reveals embryonic origin of adult satellite cells. *Genesis*. 2010; 48:424–436. [PubMed: 20641127]
41. Atit R, et al.  $\beta$ -catenin activation is necessary and sufficient to specify the dorsal dermal fate in the mouse. *Dev Biol*. 2006; 296:164–176. [PubMed: 16730693]
42. Wang W, et al. Ebf2 is a selective marker of brown and beige adipogenic precursor cells. *Proc Natl Acad Sci USA*. 2014; 111:14466–14471. [PubMed: 25197048]
43. Ohno H, Shinoda K, Ohyama K, Sharp LZ, Kajimura S. EHMT1 controls brown adipose cell fate and thermogenesis through the PRDM16 complex. *Nature*. 2013; 504:163–167. This paper reports the identification of EHMT1 as the key epigenetic regulator of BAT development and its role in whole-body energy metabolism. [PubMed: 24196706]
44. Harms MJ, et al. Prdm16 is required for the maintenance of brown adipocyte identity and function in adult mice. *Cell Metab*. 2014; 19:593–604. [PubMed: 24703692]
45. Ishibashi J, et al. An Evi1-C/EBP $\beta$  complex controls peroxisome proliferator-activated receptor  $\gamma$ 2 gene expression to initiate white fat cell differentiation. *Mol Cell Biol*. 2012; 32:2289–2299. [PubMed: 22473998]
46. Park JH, et al. A multifunctional protein, EWS, is essential for early brown fat lineage determination. *Dev Cell*. 2013; 26:393–404. [PubMed: 23987512]

47. Zhou H, Wan B, Grubisic I, Kaplan T, Tjian R. TAF7L modulates brown adipose tissue formation. *eLife*. 2014; 3:e02811.
48. Karamitri A, Shore AM, Docherty K, Speakman JR, Lomax MA. Combinatorial transcription factor regulation of the cyclic AMP-response element on the *Pgc-1 $\alpha$*  promoter in white 3T3-L1 and brown HIB-1B preadipocytes. *J Biol Chem*. 2009; 284:20738–20752. [PubMed: 19491401]
49. Jimenez-Preitner M, et al. Plac8 is an inducer of C/EBP $\beta$  required for brown fat differentiation, thermoregulation, and control of body weight. *Cell Metab*. 2011; 14:658–670. [PubMed: 21982742]
50. Chen Y, et al. miR-155 regulates differentiation of brown and beige adipocytes via a bistable circuit. *Nat Commun*. 2013; 4:1769. [PubMed: 23612310]
51. Mori M, Nakagami H, Rodriguez-Araujo G, Nimura K, Kaneda Y. Essential role for miR-196a in brown adipogenesis of white fat progenitor cells. *PLoS Biol*. 2012; 10:e1001314. [PubMed: 22545021]
52. Jin Q, et al. Gcn5 and PCAF regulate PPAR $\gamma$  and Prdm16 expression to facilitate brown adipogenesis. *Mol Cell Biol*. 2014; 34:3746–3753. [PubMed: 25071153]
53. Lee JE, et al. H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. *eLife*. 2013; 2:e01503. [PubMed: 24368734]
54. Dempersmier J, et al. Cold-inducible Zfp516 activates UCP1 transcription to promote browning of white fat and development of brown fat. *Mol Cell*. 2015; 57:235–246. [PubMed: 25578880]
55. Villanueva CJ, et al. Adipose subtype-selective recruitment of TLE3 or Prdm16 by PPAR $\gamma$  specifies lipid storage versus thermogenic gene programs. *Cell Metab*. 2013; 17:423–435. [PubMed: 23473036]
56. Stine RR, et al. EBF2 promotes the recruitment of beige adipocytes in white adipose tissue. *Mol Metab*. 2016; 5:57–65. [PubMed: 26844207]
57. Seale P, et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. *J Clin Invest*. 2011; 121:96–105. [PubMed: 21123942]
58. Ohno H, Shinoda K, Spiegelman BM, Kajimura S. PPAR $\gamma$  agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. *Cell Metab*. 2012; 15:395–404. [PubMed: 22405074]
59. Cohen P, et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. *Cell*. 2014; 156:304–316. [PubMed: 24439384]
60. Kajimura S, et al. Regulation of the brown and white fat gene programs through a PRDM16/CtBP transcriptional complex. *Genes Dev*. 2008; 22:1397–1409. [PubMed: 18483224]
61. Scime A, et al. Rb and p107 regulate preadipocyte differentiation into white versus brown fat through repression of PGC-1 $\alpha$ . *Cell Metab*. 2005; 2:283–295. [PubMed: 16271529]
62. Cederberg A, et al. *FOXC2* is a winged helix gene that counteracts obesity, hypertriglyceridemia, and diet-induced insulin resistance. *Cell*. 2001; 106:563–573. This paper reports the identification of FOXC2 as the first cell-autonomous transcriptional activator of beige adipocyte development and thermogenesis, and further demonstrates the importance of beige fat in whole-body energy homeostasis. [PubMed: 11551504]
63. McDonald ME, et al. Myocardin-related transcription factor a regulates conversion of progenitors to beige adipocytes. *Cell*. 2015; 160:105–118. [PubMed: 25579684]
64. Long JZ, et al. A smooth muscle-like origin for beige adipocytes. *Cell Metab*. 2014; 19:810–820. [PubMed: 24709624]
65. Yadav H, et al. Protection from obesity and diabetes by blockade of TGF- $\beta$ /Smad3 signaling. *Cell Metab*. 2011; 14:67–79. [PubMed: 21723505]
66. Koncarevic A, et al. A novel therapeutic approach to treating obesity through modulation of TGF $\beta$  signaling. *Endocrinology*. 2012; 153:3133–3146. [PubMed: 22549226]
67. Bi P, et al. Inhibition of Notch signaling promotes browning of white adipose tissue and ameliorates obesity. *Nat Med*. 2014; 20:911–918. [PubMed: 25038826]
68. Cinti, S. *The Adipose Organ*. Editrice Kurtis; 1999.
69. Kozak UC, et al. An upstream enhancer regulating brown-fat-specific expression of the mitochondrial uncoupling protein gene. *Mol Cell Biol*. 1994; 14:59–67. [PubMed: 8264627]


70. Cao W, et al. p38 mitogen-activated protein kinase is the central regulator of cyclic AMP-dependent transcription of the brown fat uncoupling protein 1 gene. *Mol Cell Biol.* 2004; 24:3057–3067. This paper provides a molecular mechanism by which  $\beta$ -AR signalling is integrated into the transcriptional activation of thermogenic genes through p38 MAPK-mediated phosphorylation. [PubMed: 15024092]
71. Rim JS, Xue B, Gawronska-Kozak B, Kozak LP. Sequestration of thermogenic transcription factors in the cytoplasm during development of brown adipose tissue. *J Biol Chem.* 2004; 279:25916–25926. [PubMed: 15073176]
72. Collins S.  $\beta$ -adrenoceptor signaling networks in adipocytes for recruiting stored fat and energy expenditure. *Front Endocrinol.* 2011; 2:102.
73. Karamanlidis G, Karamitri A, Docherty K, Hazlerigg DG, Lomax MA. C/EBP $\beta$  reprograms white 3T3-L1 preadipocytes to a brown adipocyte pattern of gene expression. *J Biol Chem.* 2007; 282:24660–24669. [PubMed: 17584738]
74. Li F, et al. Histone deacetylase 1 (HDAC1) negatively regulates thermogenic program in brown adipocytes via coordinated regulation of H3K27 deacetylation and methylation. *J Biol Chem.* 2016; 291:4523–4536. [PubMed: 26733201]
75. Shinoda K, et al. Phosphoproteomics identifies CK2 as a negative regulator of beige adipocyte thermogenesis and energy expenditure. *Cell Metab.* 2015; 22:997–1008. [PubMed: 26525534]
76. Puigserver P, et al. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell.* 1998; 92:829–839. This paper reports the identification of PGC1 $\alpha$ , the master regulator of mitochondrial biogenesis, and the thermogenic gene programme in BAT. [PubMed: 9529258]
77. Tiraby C, et al. Acquisition of brown fat cell features by human white adipocytes. *J Biol Chem.* 2003; 278:33370–33376. [PubMed: 12807871]
78. Iida S, Chen W, Nakadai T, Ohkuma Y, Roeder RG. PRDM16 enhances nuclear receptor-dependent transcription of the brown fat-specific *Ucp1* gene through interactions with Mediator subunit MED1. *Genes Dev.* 2015; 29:308–321. [PubMed: 25644605]
79. Chen W, Yang Q, Roeder RG. Dynamic interactions and cooperative functions of PGC-1 $\alpha$  and MED1 in TR $\alpha$ -mediated activation of the brown-fat-specific *UCP-1* gene. *Mol Cell.* 2009; 35:755–768. [PubMed: 19782026]
80. Kong X, et al. IRF4 is a key thermogenic transcriptional partner of PGC-1 $\alpha$ . *Cell.* 2014; 158:69–83. [PubMed: 24995979]
81. Hallberg M, et al. A functional interaction between RIP140 and PGC-1 $\alpha$  regulates the expression of the lipid droplet protein CIDEA. *Mol Cell Biol.* 2008; 28:6785–6795. [PubMed: 18794372]
82. Wang H, et al. Liver X receptor  $\alpha$  is a transcriptional repressor of the uncoupling protein 1 gene and the brown fat phenotype. *Mol Cell Biol.* 2008; 28:2187–2200. [PubMed: 18195045]
83. Picard F, et al. SRC-1 and TIF2 control energy balance between white and brown adipose tissues. *Cell.* 2002; 111:931–941. [PubMed: 12507421]
84. Pan D, Fujimoto M, Lopes A, Wang YX. Twist-1 is a PPAR $\delta$ -inducible, negative-feedback regulator of PGC-1 $\alpha$  in brown fat metabolism. *Cell.* 2009; 137:73–86. [PubMed: 19345188]
85. Hansen JB, et al. Retinoblastoma protein functions as a molecular switch determining white versus brown adipocyte differentiation. *Proc Natl Acad Sci USA.* 2004; 101:4112–4117. [PubMed: 15024128]
86. Christian M, et al. RIP140-targeted repression of gene expression in adipocytes. *Mol Cell Biol.* 2005; 25:9383–9391. [PubMed: 16227589]
87. Powelka AM, et al. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. *J Clin Invest.* 2006; 116:125–136. [PubMed: 16374519]
88. Leonardsson G, et al. Nuclear receptor corepressor RIP140 regulates fat accumulation. *Proc Natl Acad Sci USA.* 2004; 101:8437–8442. [PubMed: 15155905]
89. Uldry M, et al. Complementary action of the PGC-1 coactivators in mitochondrial biogenesis and brown fat differentiation. *Cell Metab.* 2006; 3:333–341. [PubMed: 16679291]
90. Lin J, et al. Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1 $\alpha$  null mice. *Cell.* 2004; 119:121–135. [PubMed: 15454086]

91. Bordicchia M, et al. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. *J Clin Invest.* 2012; 122:1022–1036. [PubMed: 22307324]
92. Petrovic N, et al. Chronic peroxisome proliferator-activated receptor  $\gamma$  (PPAR $\gamma$ ) activation of epididymally derived white adipocyte cultures reveals a population of thermogenically competent, UCP1-containing adipocytes molecularly distinct from classic brown adipocytes. *J Biol Chem.* 2009; 285:7153–7164. [PubMed: 20028987]
93. Rong JX, et al. Adipose mitochondrial biogenesis is suppressed in *db/db* and high-fat diet-fed mice and improved by rosiglitazone. *Diabetes.* 2007; 56:1751–1760. [PubMed: 17456854]
94. Wilson-Fritch L, et al. Mitochondrial remodeling in adipose tissue associated with obesity and treatment with rosiglitazone. *J Clin Invest.* 2004; 114:1281–1289. [PubMed: 15520860]
95. Sell H, et al. Peroxisome proliferator-activated receptor  $\gamma$  agonism increases the capacity for sympathetically mediated thermogenesis in lean and *ob/ob* mice. *Endocrinology.* 2004; 145:3925–3934. [PubMed: 15131020]
96. Fukui Y, Masui S, Osada S, Umesono K, Motojima K. A new thiazolidinedione, NC-2100, which is a weak PPAR- $\gamma$  activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAY obese mice. *Diabetes.* 2000; 49:759–767. [PubMed: 10905484]
97. Vernochet C, et al. C/EBP $\alpha$  and the corepressors CtBP1 and CtBP2 regulate repression of select visceral white adipose genes during induction of the brown phenotype in white adipocytes by peroxisome proliferator-activated receptor  $\gamma$  agonists. *Mol Cell Biol.* 2009; 29:4714–4728. [PubMed: 19564408]
98. Tai TA, et al. Activation of the nuclear receptor peroxisome proliferator-activated receptor  $\gamma$  promotes brown adipocyte differentiation. *J Biol Chem.* 1996; 271:29909–29914. [PubMed: 8939934]
99. Sears IB, MacGinnitie MA, Kovacs LG, Graves RA. Differentiation-dependent expression of the brown adipocyte uncoupling protein gene: regulation by peroxisome proliferator-activated receptor gamma. *Mol Cell Biol.* 1996; 16:3410–3419. [PubMed: 8668156]
100. Viswakarma N, et al. Transcriptional regulation of Cidea, mitochondrial cell death-inducing DNA fragmentation factor  $\alpha$ -like effector A, in mouse liver by peroxisome proliferator-activated receptor  $\alpha$  and  $\gamma$ . *J Biol Chem.* 2007; 282:18613–18624. [PubMed: 17462989]
101. Sugii S, et al. PPAR $\gamma$  activation in adipocytes is sufficient for systemic insulin sensitization. *Proc Natl Acad Sci USA.* 2009; 106:22504–22509. [PubMed: 20018750]
102. Step SE, et al. Anti-diabetic rosiglitazone remodels the adipocyte transcriptome by redistributing transcription to PPAR $\gamma$ -driven enhancers. *Genes Dev.* 2014; 28:1018–1028. [PubMed: 24788520]
103. Qiang L, et al. Brown remodeling of white adipose tissue by SirT1-dependent deacetylation of Ppar $\gamma$ . *Cell.* 2012; 150:620–632. [PubMed: 22863012]
104. Ohyama K, et al. A synergistic anti-obesity effect by a combination of capsinoids and cold temperature through promoting beige adipocyte biogenesis. *Diabetes.* 2016; 65:1410–1423. [PubMed: 26936964]
105. Schulz TJ, et al. Identification of inducible brown adipocyte progenitors residing in skeletal muscle and white fat. *Proc Natl Acad Sci USA.* 2011; 108:143–148. [PubMed: 21173238]
106. Tseng YH, et al. New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. *Nature.* 2008; 454:1000–1004. [PubMed: 18719589]
107. Bostrom P, et al. A PGC1- $\alpha$ -dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature.* 2012; 481:463–468. [PubMed: 22237023]
108. Fisher FM, et al. FGF21 regulates PGC-1 $\alpha$  and browning of white adipose tissues in adaptive thermogenesis. *Genes Dev.* 2012; 26:271–281. [PubMed: 22302939]
109. Emanuelli B, et al. Interplay between FGF21 and insulin action in the liver regulates metabolism. *J Clin Invest.* 2014; 124:515–527. [PubMed: 24401271]
110. Pascual G, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR- $\gamma$ . *Nature.* 2005; 437:759–763. [PubMed: 16127449]
111. Ghisletti S, et al. Parallel SUMOylation-dependent pathways mediate gene- and signal-specific transrepression by LXRs and PPAR $\gamma$ . *Mol Cell.* 2007; 25:57–70. [PubMed: 17218271]

112. Lu C, Thompson CB. Metabolic regulation of epigenetics. *Cell Metab.* 2012; 16:9–17. [PubMed: 22768835]
113. Carey BW, Finley LW, Cross JR, Allis CD, Thompson CB. Intracellular  $\alpha$ -ketoglutarate maintains the pluripotency of embryonic stem cells. *Nature.* 2015; 518:413–416. [PubMed: 25487152]
114. Lu C, et al. IDH mutation impairs histone demethylation and results in a block to cell differentiation. *Nature.* 2012; 483:474–478. This study reports that a change in metabolite (2HG) levels caused by IDH mutations inhibits histone demethylation and affects lineage-specific gene expression, revealing a mechanism by which metabolites control adipocyte development. [PubMed: 22343901]
115. Wellen KE, et al. ATP-citrate lyase links cellular metabolism to histone acetylation. *Science.* 2009; 324:1076–1080. [PubMed: 19461003]
116. Moussaieff A, et al. Glycolysis-mediated changes in acetyl-CoA and histone acetylation control the early differentiation of embryonic stem cells. *Cell Metab.* 2015; 21:392–402. [PubMed: 25738455]
117. Stelzer Y, Shivalila CS, Soldner F, Markoulaki S, Jaenisch R. Tracing dynamic changes of DNA methylation at single-cell resolution. *Cell.* 2015; 163:218–229. [PubMed: 26406378]
118. Guenther MG, Levine SS, Boyer LA, Jaenisch R, Young RA. A chromatin landmark and transcription initiation at most promoters in human cells. *Cell.* 2007; 130:77–88. [PubMed: 17632057]
119. Meissner A, et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. *Nature.* 2008; 454:766–770. [PubMed: 18600261]
120. Lister R, et al. Human DNA methylomes at base resolution show widespread epigenomic differences. *Nature.* 2009; 462:315–322. [PubMed: 19829295]
121. Chen T, Dent SY. Chromatin modifiers and remodellers: regulators of cellular differentiation. *Nat Rev Genet.* 2014; 15:93–106. [PubMed: 24366184]
122. Voigt P, et al. Asymmetrically modified nucleosomes. *Cell.* 2012; 151:181–193. [PubMed: 23021224]
123. Bernstein BE, et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. *Cell.* 2006; 125:315–326. [PubMed: 16630819]
124. Mikkelsen TS, et al. Genome-wide maps of chromatin state in pluripotent and lineage-committed cells. *Nature.* 2007; 448:553–560. [PubMed: 17603471]
125. Zhao XY, Li S, Wang GX, Yu Q, Lin JD. A long noncoding RNA transcriptional regulatory circuit drives thermogenic adipocyte differentiation. *Mol Cell.* 2014; 55:372–382. [PubMed: 25002143]
126. Yadav N, et al. CARM1 promotes adipocyte differentiation by coactivating PPAR $\gamma$ . *EMBO Rep.* 2008; 9:193–198. [PubMed: 18188184]
127. Dixen K, et al. ERR $\gamma$  enhances UCP1 expression and fatty acid oxidation in brown adipocytes. *Obesity.* 2013; 21:516–524. [PubMed: 23404793]
128. Wang L, et al. Histone H3K9 methyltransferase G9a represses PPAR $\gamma$  expression and adipogenesis. *EMBO J.* 2013; 32:45–59. [PubMed: 23178591]
129. Tateishi K, Okada Y, Kallin EM, Zhang Y. Role of Jhd2a in regulating metabolic gene expression and obesity resistance. *Nature.* 2009; 458:757–761. [PubMed: 19194461]
130. Liu W, et al. miR-133a regulates adipocyte browning *in vivo*. *PLoS Genet.* 2013; 9:e1003626. [PubMed: 23874225]
131. Trajkovski M, Ahmed K, Esau CC, Stoffel M. MyomiR-133 regulates brown fat differentiation through Prdm16. *Nat Cell Biol.* 2012; 14:1330–1335. [PubMed: 23143398]
132. Yin H, et al. MicroRNA-133 controls brown adipose determination in skeletal muscle satellite cells by targeting Prdm16. *Cell Metab.* 2013; 17:210–224. [PubMed: 23395168]
133. Sun L, Trajkovski M. MiR-27 orchestrates the transcriptional regulation of brown adipogenesis. *Metabolism.* 2014; 63:272–282. [PubMed: 24238035]
134. Feuermann Y, et al. MiR-193b and miR-365-1 are not required for the development and function of brown fat in the mouse. *RNA Biol.* 2013; 10:1807–1814. [PubMed: 24356587]

135. Sun L, et al. Mir193b-365 is essential for brown fat differentiation. *Nat Cell Biol.* 2011; 13:958–965. [PubMed: 21743466]
136. Hu F, et al. miR-30 promotes thermogenesis and the development of beige fat by targeting RIP140. *Diabetes.* 2015; 64:2056–2068. [PubMed: 25576051]
137. Fu T, et al. MicroRNA 34a inhibits beige and brown fat formation in obesity in part by suppressing adipocyte fibroblast growth factor 21 signaling and SIRT1 function. *Mol Cell Biol.* 2014; 34:4130–4142. [PubMed: 25182532]
138. Pan D, et al. MicroRNA-378 controls classical brown fat expansion to counteract obesity. *Nat Commun.* 2014; 5:4725. [PubMed: 25145289]
139. Zhang H, et al. MicroRNA-455 regulates brown adipogenesis via a novel HIF1 $\alpha$ -AMPK-PGC1 $\alpha$  signaling network. *EMBO Rep.* 2015; 16:1378–1393. [PubMed: 26303948]
140. Kumar N, Liu D, Wang H, Robidoux J, Collins S. Orphan nuclear receptor NOR-1 enhances 3',5'-cyclic adenosine 5'-monophosphate-dependent uncoupling protein-1 gene transcription. *Mol Endocrinol.* 2008; 22:1057–1064. [PubMed: 18238829]
141. Molchadsky A, et al. p53 is required for brown adipogenic differentiation and has a protective role against diet-induced obesity. *Cell Death Differ.* 2013; 20:774–783. [PubMed: 23412343]
142. Hallenborg P, et al. p53 regulates expression of uncoupling protein 1 through binding and repression of PPAR $\gamma$  coactivator-1 $\alpha$ . *Am J Physiol Endocrinol Metab.* 2016; 310:E116–E128. [PubMed: 26578713]
143. Calo E, et al. Rb regulates fate choice and lineage commitment *in vivo*. *Nature.* 2010; 466:1110–1114. [PubMed: 20686481]
144. Gerhart-Hines Z, et al. The nuclear receptor Rev-erba controls circadian thermogenic plasticity. *Nature.* 2013; 503:410–413. [PubMed: 24162845]
145. Nam D, et al. Novel function of Rev-erba in promoting brown adipogenesis. *Sci Rep.* 2015; 5:11239. [PubMed: 26058812]
146. Zha L, et al. The histone demethylase UTX promotes brown adipocyte thermogenic program via coordinated regulation of H3K27 demethylation and acetylation. *J Biol Chem.* 2015; 290:25151–25163. [PubMed: 26306033]
147. Laurila PP, et al. USF1 deficiency activates brown adipose tissue and improves cardiometabolic health. *Sci Transl Med.* 2016; 8:323ra13.
148. Gupta RK, et al. Transcriptional control of preadipocyte determination by Zfp423. *Nature.* 2010; 464:619–623. [PubMed: 20200519]






**Figure 1. Cell type-specific chromatin states**

**a** | In stem cells, transcription of adipocyte lineage-specific genes, such as peroxisome proliferator-activated receptor- $\gamma$  (*Pparg*), is paused by the presence of bivalent histone H3 Lys4 and Lys27 trimethyl marks (H3K4me<sub>3</sub> and H3K27me<sub>3</sub>; top left). The bivalent H3K4me<sub>3</sub> and H3K9me<sub>3</sub> marks are observed in lineage-specified 3T3-L1 pre-adipocytes (top right). During adipocyte differentiation, the bivalent H3K4me<sub>3</sub> and H3K9me<sub>3</sub> marks are gradually resolved to a monovalent H3K4me<sub>3</sub> mark, followed by recruitment of phosphorylated CCAAT/enhancer-binding protein- $\beta$  (C/EBP $\beta$ ) and other transcription regulators (for example, signal transducer and activator of transcription 5A (STAT5A), glucocorticoid receptor (GR) and Mediator complexes) to the transcriptional ‘hotspot’, leading to PPAR $\gamma$  and C/EBP $\alpha$  expression. Subsequently, PPAR $\gamma$  and its co-regulators, such


as retinoid X receptor (RXR), induce adipocyte-specific gene expression (bottom). PPAR $\gamma$ -induced gene transcription occurs at active chromatin, as characterized by acetylated H2K27 (H3K27ac) marks at the enhancer regions and H3K4me3 marks at the promoter regions of adipocyte-specific genes. **b** | The chromatin landscape of cell type-selective gene loci in differentiated brown adipocytes (top) and white adipocytes (bottom). In brown adipocytes, recruitment of the PPAR $\gamma$ -containing transcriptional complex is associated with high levels of H3K27ac and abundant H3K4me3 marks at the enhancer and promoter regions of the brown adipose tissue (BAT)-selective genes, respectively. By contrast, white adipose tissue (WAT)-selective genes are in the heterochromatin state, as marked by H3K9me3 and H3K27me3. In white adipocytes, enhancer protein complexes at WAT-selective genes are associated with active histone marks, whereas BAT-selective genes are in the heterochromatin state. Pol II, RNA polymerase II.



**Figure 2. Transcriptional regulation of brown and beige adipocyte development**

**a** | During prenatal development, classical brown pre-adipocytes arise primarily from cells residing in the dermomyotome that express engrailed 1 (EN1), myogenic factor 5 (MYF5) and paired-box protein 7 (PAX7). MYOD (myoblast determination protein) and myogenin drive myogenesis in the dermomyotome, whereas a number of transcriptional regulators, together with their regulatory factors and regulatory signals, control brown pre-adipocyte fate commitment (see main text for details). **b** | Beige adipocytes emerge postnatally from a pre-adipocyte population that is positive for platelet-derived growth factor receptor- $\alpha$  (PDGFR $\alpha^+$ ) and stem cells antigen 1 (SCA1 $^+$ ), or from smooth muscle-like precursors positive for myosin heavy chain 11 (MYH11 $^+$ ). This cell population can give rise to both beige and white adipocytes. Various internal or external stimuli, such as chronic cold exposure, PPAR $\gamma$  agonists, cancer, exercise and several endocrine hormones are known to promote beige adipocyte differentiation. On a molecular level, beige adipogenesis, similarly


to brown adipogenesis, is under the control of a plethora of transcriptional regulators and signalling pathways (see main text for details). BMP7, bone morphogenetic protein 7; C/EBP $\beta$ , CCAAT-enhancer-binding protein  $\beta$ ; CtBP, carboxy-terminal binding protein; EBF2, early B cell factor 2; EWS, Ewing sarcoma; FOXC2, forkhead box protein; HDAC3, histone deacetylase 3; HOXC8, homeobox C8; KLF11, Krüppel-like factor 11; miR, microRNA; MLL4, myeloid/lymphoid or mixed-lineage leukaemia 4; MRTFA, myocardin-related transcription factor A; PCAF, P300/CBP-associated factor; PKA, protein kinase A; PLAC8, placenta-specific gene 8 protein; PPAR $\gamma$ , peroxisome proliferator-activated receptor- $\gamma$ ; PRDM, PR domain zinc-finger protein; SRF, serum response factor; TAF7L, TATA-binding protein associated factor 7L; TGF $\beta$  transforming growth factor- $\beta$ ; TLE3, transducin-like enhancer protein 3; WAT, white adipose tissue; YBX1, Y-box binding protein 1; ZFP, zinc-finger protein 16. Grey, double-headed arrows indicate protein interaction and complex formation, whereas black arrow-headed and bar-headed lines show stimulatory and inhibitory effects, respectively.



**Figure 3. Molecular mechanisms governing thermogenesis and the role of external cues in beige adipocyte biogenesis and function**

**a** | Thermogenesis in differentiated brown and beige adipocytes is highly induced by cold exposure and  $\beta$ -adrenergic receptor ( $\beta$ -AR) signalling. Various transcriptional regulators are involved in this process (see main text for details) and, collectively, these molecules control the brown- and beige-selective thermogenic gene programme, including glucose and fatty acid (FA) uptake, *Ucp1* gene expression and uncoupled cellular respiration. Grey, double-headed arrows indicate protein interaction and complex formation, whereas black arrow-headed and bar-headed lines show stimulatory and inhibitory effects, respectively. **b** | Cold and natriuretic peptides (NP) induce expression of thermogenic genes. In response to cold stimuli, catecholamine is released from the sympathetic nerve endings. Released catecholamine binds to  $\beta$ -AR and activates adenylyl cyclase (AC), leading to an increase in cAMP levels and activation of protein kinase A (PKA). Activated PKA phosphorylates JMJD1A and p38 MAPK. p38 MAPK is also phosphorylated through activating guanylyl cyclase (GC)-cGMP-protein kinase G (PKG) signalling when atrial NP (ANP) or ventricular NP (VNP) bind to the cardiac NP receptor. Activated p38 MAPK phosphorylates peroxisome proliferator-activated receptor- $\gamma$  (PPAR $\gamma$ ) co-activator 1 $\alpha$  (PGC1 $\alpha$ ) and transcription factor ATF2. ATF2 then binds to CRE elements on the *Pgc1a* gene promoter region and promotes *Pgc1a* transcription. Phosphorylated PGC1 $\alpha$  functions as a co-activator

for PPAR $\gamma$ . Phosphorylated JMJD1A forms a transcriptional complex with the SWI/SNF chromatin remodeller and PPAR $\gamma$ . The phosphorylated JMJD1A SWI/SNF PPAR $\gamma$  complex induces enhancer–promoter proximity through forming a three-dimensional long-range chromatin loop and activates the transcription of thermogenic genes (for example, *Ucp1* and *Adrb1* (adrenoceptor- $\beta$ 1)). c | Chronic treatment of subcutaneous white adipose tissue (WAT)-derived pre-adipocytes with PPAR $\gamma$  agonists (such as thiazolidinedione (TZD)) promotes beige adipocyte differentiation. This is achieved partly through PR domain zinc-finger protein 16 (PRDM16) stabilization and enhanced formation of the PRDM16–PPAR $\gamma$  complex. Chronic TZD treatment probably exerts its effects through reducing PRDM16 protein ubiquitylation and inhibiting its degradation by the proteasome. In addition, TZD can induce sirtuin 1 (*Sirt1*), which induces deacetylation of PPAR $\gamma$  and enhances the formation of the PRDM16–PPAR $\gamma$  complex. Finally, TZD treatment induces Krüppel-like factor 11 (KLF11), which then maintains the association of PPAR $\gamma$  with superenhancers of beige-selective genes. This collectively promotes activation of the beige-selective gene programme. C/EBP $\beta$ , CCAAT-enhancer-binding protein- $\beta$ ; CK2, casein kinase 2; CREB, cAMP-responsive element-binding; FOXC2, forkhead box protein C2; Gsa, stimulatory G protein subunit- $\alpha$ ; H3K27, histone H3, Lys27; HDAC, histone deacetylase; IRF4, interferon regulatory factor 4; LXR, liver X receptor; RIP140, receptor-interacting protein 140; RXR, retinoid X receptor; T3, triiodothyronine; TR, thyroid hormone receptor; TWIST1, Twist-related protein 1; *Ucp1*, uncoupling protein 1; ZFP, zinc-finger protein.



**Figure 4. Regulation of epigenetic factors by metabolites**

**a** | Various metabolites can affect chromatin states by acting as cofactors for epigenetic regulators involved in adipogenesis. Acetyl-CoA and *S*-adenosyl methionine (SAM) are donors for histone acetyltransferases (HATs) and histone and DNA methyltransferases (HMTs and DNMTs), respectively. NAD<sup>+</sup> and ATP regulate sirtuin demethylases (SIRT6) and kinases, respectively.  $\alpha$ -ketoglutarate ( $\alpha$ KG) is a cofactor of JMJD histone demethylases (JMJDs) and 5-methylcytosine hydroxylases (also known as TETs). **b** | Metabolites and changes in metabolic pathways can affect adipogenesis. Isocitrate dehydrogenase (IDH) catalyses isocitrate to produce  $\alpha$ KG in the tricarboxylic acid (TCA) cycle. However, mutations in the *IDH* gene lead to the production of 2-hydroxyglutarate (2HG) from  $\alpha$ KG, which in turn inhibits enzymatic activities of the  $\alpha$ KG-dependent histone and DNA demethylases, such as JMJD and TETs, thereby inhibiting adipogenesis.

Table 1

Transcriptional and epigenetic regulators of brown and beige adipocyte development

Factors	Activity	Effectors and interacting partners	Role in brown adipocyte development	Role in beige adipocyte development	Refs
Blncl	Long non-coding RNA (lncRNA)	EBF2	Yes (promoting in culture cells)	Yes (promoting in culture cells)	125
C/EBP $\beta$	Transcriptional factor	PRDM16	Yes (promoting)	Yes (promoting)	17,48
CARM1	Arg methyltransferase	PPAR $\gamma$	Yes (reduced BAT in knockout mice)	NA	126
CREB, ATF2	Transcription factor	CBP	Yes (promoting UCP1 expression)	Yes (promoting UCP1 expression)	69–71
CtBP1, CtBP2	Transcriptional repressor	PRDM16	NA	Yes (repressing WAT gene expression)	60,97
EBF2	Transcription factor	PRDM16	Yes (promoting)	Yes (promoting)	34,42,56
EHMT1	H3K9 methyltransferase	PRDM16	Yes (reduced BAT in knockout mice)	Yes (promoting)	43,44
ERR $\gamma$	Nuclear receptor	PGC1 $\alpha$	Yes (promoting UCP1 expression)	NA	127
EWS	Transcriptional repressor, RNA-binding protein	YBX1, BMP7	Yes (reduced BAT in knockout mice)	NA	46
FOXC2	Transcription factor	PKA	Yes (promoting)	Yes (promoting)	62
G9A (EHMT2)	H3K9 methyltransferase	PPAR $\gamma$	Yes (inhibiting brown adipogenesis)	NA	128
GCN5	Acetyltransferase	PPAR $\gamma$ , C/EBP $\beta$ , PRDM16	Yes (reduced BAT in <i>GCN5/PCAF</i> double-knockout mice)	NA	52
HES1	Transcription factor (downstream of Notch)	PRDM16, PGC1 $\alpha$	No	Yes (inhibiting)	67
IRF4	Transcription factor	PGC1 $\alpha$	Yes (promoting)	Yes (promoting)	80
IRX3, IRX5	Transcription factor	PRDM16, PGC1 $\alpha$	NA	Yes (inhibiting)	38
JMJD1 (JHDM2A)	H3K27 demethylase	PPAR $\gamma$	Yes (promoting)	NA	39,129
JMJD3	H3K9 demethylase	RREB1	Yes (promoting BAT gene expression)	Yes (promoting beige gene expression)	35
KLF11	Transcription factor	PPAR $\gamma$	NA	Yes (promoting in culture cells)	36
LXR	Nuclear receptor	RIP140	Yes (inhibiting UCP1 gene expression)	Yes (inhibiting beige gene expression)	82
miR-133	microRNA	PRDM16	Yes (inhibiting)	Yes (inhibiting)	130–132
miR-155	microRNA	C/EBP $\beta$	Yes (inhibiting)	Yes (inhibiting)	50
miR-27	microRNA	PRDM16, PPAR $\alpha$ , PPAR $\gamma$ , CREB, PGC1 $\beta$	Yes (inhibiting in culture cells)	Yes (inhibiting in culture cells)	133



Factors	Activity	Effectors and interacting partners	Role in brown adipocyte development	Role in beige adipocyte development	Refs
miR-193b-365	microRNA	RUNX1T1	Yes (promoting in culture cells) or No (no change in BAT in knockout mice)	NA	134,135
miR-196a	microRNA	HOXC8, C/EBP $\beta$	No	Yes (promoting)	51
miR-30	microRNA	RIP140	Yes (promoting)	Yes (promoting)	136
miR-34a	microRNA	FGFR1, SIRT1	Yes (inhibiting)	Yes (inhibiting)	137
miR-378	microRNA	PDE1B	Yes (promoting)	No	138
miR-455	microRNA	RUNX1T1, Necdin, HIF1AN	Yes (promoting)	Yes (promoting)	139
MLL4	H3K4 methyltransferase	PPAR $\gamma$ , C/EBP $\alpha$ , C/EBP $\beta$	Yes (reduced BAT in knockout mice)	NA	53
MRTFA	Transcription factor	SRF, BMP7	No	Yes (inhibiting)	63
NUR77	Nuclear receptor (orphan)	cAMP	Yes (promoting UCP1 expression)	NA	140
p107	Pocket protein family	PRDM16, PGC1 $\alpha$	Yes (inhibiting)	Yes (inhibiting)	61
p53	Tumour suppressor	PGC1 $\alpha$	Yes (reduced BAT gene expression in knockout mice) or no change	Yes (inhibiting)	141,142
PGC1 $\alpha$	Transcriptional co-activator	PPAR $\gamma$ , PRDM16 and others	Yes (promoting)	Yes (promoting)	76,77, 89,90
PLAC8	Transcriptional co-activator	C/EBP $\beta$	Yes (reduced BAT in knockout mice)	NA	49
PPAR $\gamma$	Nuclear receptor	PRDM16, PGC1 $\alpha$ and others	Yes (promoting)	Yes (promoting)	22,23, 58
PRDM16	Transcriptional co-activator/repressor	PPAR $\gamma$ , C/EBP $\beta$ , EHMT1 and others	Yes (promoting)	Yes (promoting)	17-19, 59
PRDM3	Transcriptional co-activator	C/EBP $\beta$ , EHMT1	Yes (reduced BAT gene expression in <i>PRDM16/PRDM3</i> double-knockout mice)	NA	44,45
Rb	Pocket protein family	PPAR $\gamma$	Yes (increased BAT in knockout mice)	Yes (inhibiting)	85,143
REV-ERB $\alpha$	Nuclear receptor	TGF $\beta$	Yes (inhibiting UCP1 expression or promoting brown adipogenesis)	NA	144,145
RIP140	Transcriptional repressor	PGC1 $\alpha$ , LXR	No	Yes (inhibiting beige gene expression)	86-88
SIRT1	Deacetylase	PPAR $\gamma$	No	Yes (promoting)	103
SMAD3	Transcription factor (downstream of TGF $\beta$ )	PRDM16, PGC1 $\alpha$	Yes (inhibiting)	Yes (inhibiting)	65
SRC2 (TIF2)	Transcriptional co-regulator	PGC1 $\alpha$	Yes (inhibiting)	NA	83
TAF7L	TATA-binding protein-associated factor	PPAR $\gamma$ , PRDM16	Yes (reduced BAT in knockout mice)	NA	47
TLE3	Transcriptional repressor	PRDM16	Yes (inhibiting)	Yes (inhibiting)	55
TWIST1	Transcription factor	PGC1 $\alpha$	Yes (inhibiting brown thermogenesis gene)	Yes (inhibiting)	84

Factors	Activity	Effectors and interacting partners	Role in brown adipocyte development	Role in beige adipocyte development	Refs
UTX	H3K27 demethylase	CBP	Yes (promoting in culture cells)	NA	146
USF1	Transcription factor	Unknown	Yes (increased BAT thermogenesis in knockout mice)	NA	147
ZFP423	Transcription factor	PPAR $\gamma$ , SMAD	Yes (reduced BAT in knockout mice)	NA	148
ZFP516	Transcription factor	PRDM16	Yes (promoting)	Yes (promoting)	54

BAT, brown adipose tissue; BMP7, bone morphogenetic protein 7; CBP, CREB-binding protein; C/EBP, CCAAT/enhancer-binding protein; CREB, cAMP-responsive element-binding; CIBP, carboxy-terminal binding protein; EBF2, early B cell factor 2; ERK $\gamma$ , oestrogen-related receptor- $\gamma$ ; EWS, Ewing sarcoma; FGFR1, fibroblast growth factor receptor 1; FOXC2, forkhead box protein C2; H3K4, histone H3, Lys4; H3K27, histone H3, Lys27; HIF1AN, hypoxia-inducible factor-1 $\alpha$  inhibitor; HOXC8, homeobox protein C8; IRF4, interferon regulatory factor 4; KLF11, Krüppel-like factor 11; LXR, liver X receptor; MLL4, myeloid/lymphoid or mixed-lineage leukaemia 4; MRTFA, myocardin-related transcription factor A; NA, not available; PCAF, P300/CBP-associated factor; PDE1B, calcitriol/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1B; PGC1, PPAR $\gamma$  co-activator-1; PKA, protein kinase A; PLAC8, placenta-specific gene 8 protein; PPAR $\gamma$ , peroxisome proliferator-activated receptor- $\gamma$ ; PRDM16, PR domain zinc-finger protein 16; RIP140, receptor-interacting protein 140; RREB1, Ras-responsive element-binding protein 1; RUNX1, RUNX1 translocation partner 1; SIRT1, sirtuin 1; SRF, serum response factor; TAF7L, TATA-binding protein associated factor 7L; TGF $\beta$ , transforming growth factor- $\beta$ ; TLE3, transducin-like enhancer protein 3; TWIST1, Twist-related protein 1; UCPI1, uncoupling protein 1; USF1, upstream stimulatory factor 1; WAT, white adipose tissue; YBX1, Y-box binding protein 1; ZFP, zinc-finger protein.